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ABSTRACT 
 
 
The gene expression profile of a eukaryotic cell is responsive to a variety of extracellular 
stimuli, including nutrient availability, which allows cells to toggle between anabolism 
and catabolism based on the favorability of their environment. Much of this information 
is relayed through signaling complexes, such as the target of rapamycin complex 1 
(TORC1), to downstream chromatin modifying enzymes. These enzymes impact the gene 
regulatory process through altered histone post-translation modifications, changes in 
chromatin structure, and docking of chromatin regulatory complexes. Yet, despite 
preliminary studies suggesting that TORC1 affects epigenetic mechanisms, including 
histone H3 lysine 56 acetylation (H3K56ac), almost nothing is known about how the 
complex functions in this regard. In this report, we demonstrate that inhibition of TORC1 
results in a site-specific reduction in acetylation on N-terminal residues of both histone 
H3 and H4. This effect is dependent on sirtuin histone deacetylases (HDACs), as 
inactivation of these enzymes, specifically Hst4, rescues the acetylation defect. We also 
find that this sirtuin-mediated deacetylation response requires a functional protein 
phosphatase 6 complex (PP6). PP6 is under direct negative regulation of TORC1, and 
relief of this inhibition initiates a rapid cytoplasmic to nuclear redistribution of Hst4 
which correlates temporally with our observed loss of histone acetylation. The nuclear 
accumulation of Hst4 precedes an increase in Hst4 protein levels that occurs due to a 
reduction in Hst4 turnover. Notably, deletion of a subset of sirtuins (hst3Δ or hst4Δ) 
rescued the sensitivity of a non-essential TORC1 mutant (tco89Δ) to an array of TORC1 
inhibitors. This result suggests the link between TORC1 and acetylation may play an 
essential role in cell cycle regulation and the DNA damage response. We further 
evaluated whether these TORC1-mediated acetylation marks contribute to the chromatin 
association of high mobility group proteins (HMGs). And while TORC1-dependent 
displacement of the HMGs coincides with vacuolar acidification, hyperactivation of 
TORC1, and significant cell death, it appears to occur independently of TORC1’s 
regulation of Hst4. We conclude by investigating mitochondrial function in a tco89Δ 
mutant and mapping the functional domains of Tco89 necessary to sustain TORC1 
activity and respond to extracellular stress. 
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CHAPTER 1.    INTRODUCTION 
 
 
Histone Proteins and Chromatin Organization 
 
 The histone family of DNA packaging proteins is comprised of four isoforms: 
H2A, H2B, H3 and H4. Each histone consists of a globular core and a pair of N- and C-
terminal tails. All of the core histones exist as heterodimers of H2A/H2B or H3/H4, and 
assembly of four of these heterodimers (two of each) results in formation of an octameric 
structure collectively known as the nucleosome [1, 2]. Approximately 146 base pairs of 
DNA are wound around each nucleosome, resulting in the “beads on a string” structure, 
noted initially in early electron microscopy analyses of intact chromatin [3]. From there, 
interactions between the nucleosomes themselves produce a more compacted form of 
chromatin known as the 30 nm fiber. Additional higher order folding and packaging 
condenses the 30 nm fiber even further to ultimately form chromosomes (Figure 1-1). 
 
 
The Epigenome 
 
 The epigenome consists of a heritable set of highly complex histone post-
translation modifications, including acetylation, methylation, phosphorylation and 
ubiquitination, which essentially establish a secondary layer of genetic information that is 
stored above the chromatin. These epigenetic moieties occur predominantly on the N-
terminal tails of the histones (Figure 1-2), where they function to coordinate a multitude 
of chromatin-based processes; most notably, enabling changes to an organism’s 
phenotype through adjustments in gene expression rather than alterations to the genotype. 
Methylation of lysines and arginines on the histone tails has a very context specific effect 
on transcription, which is most often coordinated through mediating the association of 
methyl-binding proteins (i.e. Tudor domains, MBT domains, PHD domains, 
chromodomains, and WD proteins) [4-11]. On the other hand, acetylation status of these 
residues impacts the availability of the histone’s positively charged amino groups to bind 
to the negatively charged DNA backbone. Specifically, increased acetylation results in a 
more open and transcriptionally accessible chromatin state, while reduction in these 
marks promotes a more heterochromatic and transcriptionally occlusive environment 
(Figure 1-3). Intriguingly, histone acetylation at the ribosomal protein (RP) genes and the 
ribosomal DNA (rDNA) has been shown to be responsive to signaling through nutrient 
sensing complexes [12, 13]. This suggests that epigenetic mechanisms could coordinate 
changes in gene expression in response to environmental nutrient availability. Despite a 
recent swell of scientific and mainstream interest, there are some who still believe the 
importance of the histone code and transgenerational epigenetic inheritance has been 
overstated [14-19].  
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Figure 1-1. Cartoon representation of chromatin packaging. 
DNA is spooled around the nucleosomes to form a loosely condensed, 11 nm fiber, 
sometimes referred to as the “beads on a string” configuration. Nucleosomal interactions 
drive additional levels of chromatin packaging, ultimately leading to the formation of 
chromosomal DNA. See text for more details. Reprinted with permission [20]. DNA 
Packaging - Shmoop Biology. 2008  [cited 2016 May 11]; Available from: 
http://www.shmoop.com/dna/dna-packaging.html.  
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Figure 1-2. Schematic of the nucleosome. 
The nucleosome is a histone octamer complex which consists of two heterodimers of 
both H2A/H2B and H3/H4. The most topical post-translation modifications on the N-
terminal tails of each histone are denoted.   
 4 
 
 
Figure 1-3. Transcriptional availability of DNA is mediated by the epigenetic 
modifications of histones. 
Cartoon representation of the dynamic effects acetylation and methylation can have on 
chromatin packaging, and subsequently, the accessibility of particular regions of DNA 
for efficient gene transcription. Reprinted with permission [20]. DNA Packaging - 
Shmoop Biology. 2008  [cited 2016 May 11]; Available from: 
http://www.shmoop.com/dna/dna-packaging.html.  
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Advantages of the S. cerevisiae Model System for Epigenetic Studies 
 
 The study of chromatin, particularly at single nucleosome resolution, proves very 
challenging in most models or cell lines due to the multicopy nature of the core histone 
genes. As an example, human cells have 15 copies of the H3 gene, encoding canonical 
H3 and two additional H3 sequence variants [21, 22]. This high level of redundancy 
makes probing the specific chromatin contributions of individual histone amino acid 
residues incredibly difficult. However, due to the evolutionary conservation of the core 
histones, and because the budding yeast genome encodes only two copies of canonical 
H3 and H4, S. cerevisiae has become an essential model organism for conducting cutting-
edge, mechanism-based experiments that are highly translatable. Indeed, our current 
knowledge of functional genomics, histone dynamics and epigenetic modifications was 
built on work conducted in budding yeast [23].  
 
 
Coordination of Nutrient Availability, Anabolism and Cellular Aging 
 
 It is critical for all eukaryotic organisms to be able to rapidly adjust their growth 
and proliferative profiles to account for changing extracellular conditions or intracellular 
deficits. This principle is most critical as it relates to active cell division, as an inability to 
coordinate mitosis with nutrient and energy states may prevent sufficient biomass 
accumulation and have adverse downstream consequences on cell viability [24-27]. In 
response to these pressures, cells have developed highly conserved nutrient sensing 
complexes, such as the target of rapamycin complex 1 (TORC1), which couples 
extracellular nutrient signals with the appropriate intracellular response [28]. Aberrant 
flux through these sensing pathways contributes to a number of age-related diseases, 
including diabetes, cancer and cardiovascular disease [29].  
 
 
Identification of the Target of Rapamycin Genes 
 
 The discovery of target of rapamycin (Tor), a protein kinase responsible for 
mediating cell growth and proliferation in coordination with growth factors and 
environmental nutrient status, can be traced back to the isolation of rapamycin, a 
macrolide produced by the Easter Island soil bacterium Streptomyces hygroscopicus [30]. 
Though once a promising antifungal compound, rapamycin’s adverse effects on host T-
cell proliferation has led to its present day use as an immunosuppressant and anti-cancer 
agent (as reviewed by Benjamin)[31]. The rapamycin-dependent effects on T-cell 
proliferation require the FK506-binding protein (FKBP), a binding partner now known to 
bridge the association of rapamycin and the FKBP-rapamycin binding domain of Tor [32-
34].  
 
 The proliferation defect first identified in rapamycin treated T-cells is also  
observed in the budding yeast Saccharomyces cerevisiae, and in both instances, 
deficiencies are attributable to an early G1 cell-cycle arrest [35]. Genome sequencing of 
spontaneously rapamycin resistant yeast mutants identified the two genes responsible for 
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mediating the rapamycin phenotype, and they were aptly named target of rapamycin 1 
and 2 (TOR1 and TOR2) [35]. These genes encode a unique pair of PI3-like 
serine/threonine kinases. Subsequently, an orthologous kinase was discovered in higher 
order organisms, termed mechanistic TOR (mTor), and since then, Tor kinases have been 
reported to be conserved across all eukaryotes [36-38]. Characterization of Tor kinase 
substrates has proven difficult due to the lack of a true consensus sequence, though a few 
are known and will be discussed below. For clarity and simplicity, nomenclature for the 
yeast Tor pathway will be used from herein unless otherwise noted. 
 
 
The TORC1 Complex 
 
 The Tor kinases are incorporated into one of two signaling complexes: target of 
rapamycin complex 1 or 2 (TORC1/2) [39-41]. In metazoans, these complexes are known 
as mechanistic TORC1/2 (mTORC1/2). There are considerable structural and functional 
differences between TORC1 and TORC2, the most relevant being that TORC1 is 
sensitive to environmental stimuli and rapamycin-dependent inhibition while TORC2 is 
not. Because the overarching interest of our lab is in environmentally regulated 
epigenetic processes, TORC1 will be our focus for the remainder of this work.  
 
 TORC1 consists of the Tor1/2 kinase, Lst8, Kog1, and Tco89 [42]. Lst8 and the 
Tor2 kinase can be found in both TORC1 and TORC2, but Tor1, Kog1 and Tco89 appear 
to be TORC1-specific [43]. Accordingly, temperature sensitive mutants of Kog1 
(essential), or tco89Δ mutants (non-essential), sensitize cells to direct TORC1 inhibition 
[43, 44]. Electron microscopy studies have characterized the association between the C-
terminal WD40 domain of Kog1 and the N-terminal HEAT repeats of the Tor kinases 
[45]. Kog1 and its mammalian ortholog, Raptor, contribute to TORC1 function by 
facilitating a series of interactions, including between the kinase and its substrates [46, 
47], and between TORC1 and the vacuole (discussed in detail below) [48, 49]. Further, 
when nutrients are limiting, the Rho1 GTPase associates with Kog1, resulting in 
inhibition of TORC1 [50]. Recently, it was reported that TORC1-bound Kog1 is more 
stable than free Kog1, suggesting association with the complex may also serve to 
stabilize Kog1 [51].  
 
 By comparison, little is known about Tco89. It is currently believed to be a yeast-
specific component of TORC1, and homologs have been identified in S. pombe and C. 
albicans [52, 53]. The existence of a mammalian Tco89 seems likely however, given the 
considerable conservation of the TORC1 axis. tco89Δ cells have abnormal cellular 
physiology and budding patterns, as well as dramatically increased sensitivity to stress; 
including heat, caffeine, MMS, rapamycin and salt [52, 54-60]. tco89Δ mutants 
phenotypically resemble vacuole mutants (ego1Δ, ego3Δ, gtr1Δ and gtr2Δ), as these 
strains are all acutely sensitive to rapamycin and unable to reengage the cell cycle 
following TORC1 stress [43, 61] (discussed in detail later). In support of the above, 
Tco89 has been reported to mediate physical interactions between TORC1 and the 
vacuole [49]. Tco89 has also been shown to directly associate with Vac8, an armadillo 
repeat protein which affects vacuolar functions and caffeine resistance [62], and fructose-
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1,6-bisphosphate to mediate its vacuolar turnover [63]. Still, the majority of studies that 
mention tco89Δ do so in the context of suppressor screens [64, 65]. Most of these screens 
also identify tor1Δ, suggesting that Tco89’s most prominent function involves 
maintaining TORC1 activity. Interestingly, our group has shown that TORC1-dependent 
histone acetylation is responsive to tco89Δ but not tor1Δ [66]. A mammalian ortholog of 
Tco89 could be an attractive therapeutic target given the dramatic and permanent cell 
cycle arrest that occurs in its absence when sub-inhibitory doses of rapamycin are 
administered [43, 49]. 
 
 
Downstream Effectors of TORC1 
 
 When nutrient status and environmental conditions are favorable, TORC1 actively 
promotes growth programs and simultaneously suppresses stress responses through 
coordination of a downstream kinase (Sch9) and a series of Tap42-associated 
phosphatases (Figure 1-4). Conversely, diminished TORC1 signaling during times of 
starvation or rapamycin treatment causes cells to enter a quiescent state where anabolic 
flux is suppressed. Fascinatingly, long-term TORC1 inhibition, and subsequent 
suppression of anabolism, has been shown to extend lifespan across a number of model 
systems [67-74]. These rapid and dramatic changes in intracellular processes require a 
coordinated shift in gene expression, which TORC1 has been shown to regulate at the 
level of mRNA transcription (via transcription factor localization [75]) and translation (at 
the initiation step of elongation [76-78]). But how TORC1 regulates gene expression, 
particularly as it relates to chromatin structure, remains a poorly defined function of the 
pathway.  
 
 Recently, it was demonstrated that TORC1 also signals through the Ypk3 kinase 
to promote phosphorylation of the ribosomal proteins Rps6a/b, though the mechanism 
remains unclear [79]. Phosphorylation of S6 serves as a readout for TORC1 activity in 
eukaryotic cells [80], and it will be used as such in the studies presented herein. For now 
though, we will focus on the Sch9 kinase and the Tap42 phosphatases as they are the 
best-characterized effector molecules downstream of yeast TORC1 (Figure 1-4).  
 
 
Sch9 kinase 
 
 Sch9 is an AGC protein kinase whose activity is directly promoted by TORC1-
dependent phosphorylation [80]. The degree of control TORC1 exerts on Sch9 is evident 
in the fact that sch9Δ cells phenocopy the effects of caloric restriction (CR), including 
extended lifespan, and behave very similarly to a tor1Δ [71, 72, 80, 81]. It is important to 
note that there is also evidence that Sch9 and TORC1 may function synergistically, rather 
than redundantly, in sensing environmental stressors [82]. This concept is supported by 
the fact that phosphorylation of the Sch9 activation loop may occur independently of 
TORC1 via the Pkh1/2 kinases, possibly tying Sch9 into sphingolipid homeostasis as 
well as to classical TORC1 stimuli [83-85]. In the case described above, an additional  
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Figure 1-4. Downstream effectors of the TORC1 signaling pathway and their 
functions in S. cerevisiae. 
TORC1 effectors include yeast protein kinase 3 (Ypk3), the Sch9 kinase, and the Tap42-
associated phosphatases. Cellular processes mediated by each are presented as well. See 
text for more details.  
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TORC1-dependent phosphorylation mark on the hydrophobic motif of Sch9 is able to 
fine-tune the Pkh1/2-initiated activity.  
 
 The basic function of Sch9 is to promote proper cell cycle progression, 
transcription initiation, and translation, while simultaneously suppressing induction of 
autophagy [80, 86-88]. Under favorable environmental conditions, Sch9 phosphorylates 
and inhibits the transcriptional repressors Maf1, Dot6, Tod6 and Stb3, ensuring 
transcription of genes necessary for ribosomal biogenesis [60, 86, 89]. Sch9 activity also 
feeds into the suppression of autophagy, seemingly in concert with RAS/PKA, via 
regulation of the Atg1-Atg13-Atg17 kinase complex [88]. Additionally, to promote cell 
cycle progression, Sch9 targets the ubiquitin conjugating enzyme, Cdc34 [90]. An 
interesting study from Weisman et al. also ties Sch9 into cell cycle control through a 
unique vacuolar inheritance mechanism. They demonstrate that if this inheritance fails, 
the cell cycle arrests at G1 in an Sch9-dependent fashion [91]. Conversely, inhibition of 
Sch9 during times leads to Gcn2-mediated phosphorylation of the translation factor 
eIF2a, which inhibits its function and blocks protein synthesis [82]. It was also suggested 
recently that Sch9 regulation of Maf1 may contribute to CR-induced lifespan extension 
[92]. 
 
 
The PP6 phosphatase complex and Tap42 
  
 The Tap42-associated phosphatases are a family of functionally distinct, modular 
protein phosphatase complexes, which include PP2A, PP4, PP6 and PPG1 [93-96]. These 
complexes are best known as regulators of non-preferred nitrogen catabolism and the 
stress response. For brevity, and because PP6 will be the major focus of our work, it will 
be the only complex discussed in-depth.  
 
 The PP6 phosphatase complex exists as a heterodimer consisting of the ceramide-
responsive catalytic subunit, Sit4, and one of four Sit4-associated regulatory proteins 
(Sap4, Sap155, Sap185, or Sap190) [97]. Sit4 regulates expression of the cyclin genes 
and is required for the execution of cell cycle START (G1), bud formation, initiation of 
DNA synthesis, and spindle pole body duplication [98, 99]. Overexpression of the Saps 
in a temperature sensitive Sit4 mutant can partially reverse the observed growth defects, 
while a complete ablation of the Saps in an otherwise wild-type cell induces a sit4Δ-like 
slow growth phenotype and G1 delay [97]. Association of the catalytic and regulatory 
subunits appears to be cell-cycle dependent and indispensable for Sit4 activity in vivo. 
And while some speculate that the Saps regulate PP6 substrate specificity, their exact 
function is currently unknown. There is evidence which suggests that each Sap has a 
unique and distinct contribution to PP6 function, but there is also data that demonstrates 
at least moderate functional redundancy exists as well [97, 100, 101]. Interestingly, 
overexpression of metazoan PP6 regulatory subunits (PP6R2 and PP6R3) in the absence 
of the Saps restores growth and reverses rapamycin sensitivity, suggesting rather 
significant evolutionary conservation of this modular phosphatase complex [102].  
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 Sit4 is highly influential in the cellular response to altered nutrient states, 
particularly to changes in amino acid availability. During starvation, the Gln3, Gat1, and 
Nil1 transcription factors are dephosphorylated by Sit4, which triggers dissociation from 
their cytoplasmic anchors and entry into the nucleus [103]. There, these factors drive high 
level expression of genes encoding permeases and enzymes needed to transport and 
utilize poor nitrogen sources. At the same time, the Sit4 phosphatase is also known to 
target the Npr1 kinase, leading to its activation and the subsequent stabilization of the 
general amino acid permease Gap1 [104]. These effects are known collectively as the 
Nitrogen Catabolite Repression (NCR) response. 
 
 Tap42’s association with its family of phosphatases has a somewhat muddled 
history. It was initially identified in yeast as a 42kDa protein that specifically associates 
with the PP2A and PP6 protein phosphatase complexes [105]. Tap42 is now known to 
associate with all of the other PP2A-like phosphatase complexes, including the 
aforementioned PPG1 and PP4 [96]. Somewhat surprisingly, there is far less Tap42 in the 
cell than there are phosphatases, as only about 5-10% of cellular PP2A-like phosphatases 
are bound to Tap42 [105]. Such stoichiometry could suggest that these phosphatases 
possess Tap42-independent functions or possibly additional substrates that have yet to be 
identified. Chen et al. utilized a yeast two-hybrid screen to identify a mammalian protein 
they dubbed α4, which is also capable of binding the N-terminal portion of these 
phosphatase complexes [106]. The authors report significant sequence conservation 
between α4 and Tap42, suggesting the proteins may be homologs.  
 
 In the late 1990’s, evidence began accumulating that Tap42 and α4 act as negative 
regulators of the PP2A-like phosphatases. First, Nanahoshi’s group reported that PP2A-
dependent dephosphorylation of eIF-4E binding protein was inhibited by the presence of 
Tap42 and α4 [107]. Subsequently, Beck and Hall suggested that Tap42 and Sit4 form a 
complex following Tap42 phosphorylation by TOR, and postulated that this was the 
inactive form of the phosphatase [75]. They found that when phosphatases were 
dissociated from Tap42, this was accompanied by a dephosphorylation of many 
downstream targets, concluding that phosphatase release led to its activation. This idea 
was supported by Jiang and Broach, who later demonstrated that Tap42 association to 
Sit4 is indeed rapamycin responsive and dependent on TORC1 phosphorylation of Tap42 
[108]. Gene expression profiling identified dynamic expression level changes that mirror 
the release and disassembly of the Tap42-Sit4 complex [109]. Similarly, the inactivation 
of Tap42 was shown to severely attenuate the rapamycin-induced expression of genes 
under control of the Sit4-regulated Gln3 transcription factor [110].  
 
 More recently, however, many of the initial claims made about Tap42’s function 
as a negative regulator, as well as its identity as a homolog to α4, have been questioned. 
In 2006, it was reported that rather than Tap42 functioning as a negative regulator, it may 
actually be a positive effector of the phosphatases [111]. The timing of this paradigm-
shifting experiment proved to be key as it utilized shorter, more closely spaced time 
points than the Hall study [75]. The authors demonstrated by fractionation that Tap42-
phosphatase complexes exist primarily on membrane structures through association with 
TORC1. They also showed that the TORC1-associated population of Tap42 is almost 
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exclusively phosphorylated, while the cytoplasmic pool is not. Importantly, they reported 
that the TORC1-Tap42-Sit4 association is environmentally sensitive, as rapamycin 
treatment or nutrient starvation releases the Tap42-phosphatase complex into the cytosol. 
The cytosolic complex then dissociates further, leaving Tap42 and the free phosphatase. 
Finally, the authors demonstrated that Tap42 dephosphorylation and complex 
dissociation occurs long after phosphatase activation. These results ultimately illustrated 
that the cytoplasmic Tap42-PP6 phosphatase complex is indeed the active form, and 
that the dissociation of Tap42 from Sit4 is not the trigger for phosphatase activity as 
was previously believed. Interestingly, the interaction between Tap42 and PP6 is 
independent of whether the Saps are present [105]. 
 
 This conclusion has subsequently been supported by other groups that have 
demonstrated that phosphatase activity, and particularly Sit4 function, depends on the 
presence of Tap42 [96]. In fact, loss of Tap42 prevents Sit4-dependent stress-response 
genes from being activated [110]. It has also been reported that overexpression of Tap42 
along with these phosphatases leads to a growth inhibition phenotype that is more 
substantial than is seen with the phosphatases alone [105]. Altogether, these results show 
that Tap42 is indispensable for PP6 phosphatase activity, and we speculate that like α4 
[112], Tap42 may be functioning as a chaperone to protect the integrity of the 
phosphatase complexes.  
 
 To summarize, when conditions are favorable for growth, phosphatases are 
sequestered at the vacuole due to TORC1 phosphorylation of both Tip41, a cytoplasmic 
binding partner of Tap42, and Tap42 itself (Figure 1-5A). During the initial stages of 
nutrient stress (Figure 1-5B), the Rho1 GTPase competitively inhibits the Tap42-Kog1 
association at the vacuole, which releases and activates the Tap42-PP6 phosphatase 
complex [50]. Sit4-dependent dephosphorylation of the stress responsive transcription 
factors results in their localization to the nucleus, and a corresponding shift in the gene 
expression patterns of the cell. Later in the starvation response (Figure 1-5C), the 
TORC1-dependent phosphorylation marks on Tip41 and Tap42 are removed, although 
the responsible phosphatase remains unclear (some postulate it may actually by a self-
regulatory function of Sit4). At this point, Tip41 competes for the binding of Tap42 and 
promotes Tap42-Sit4-Sap complex disassembly [113]. This inactivating event usually 
occurs approximately 30 minutes after initial introduction of the stress, though it is 
unclear whether Sit4 remains associated with the Sap following release from Tap42 
(denoted by question mark in Figure 1-5C). Eventually, when the environment permits, 
an inactive holocomplex of Tap42-Sit4-Sap is reformed at the vacuolar surface through 
associations with active TORC1. As was mentioned above, only a small amount of the 
Sit4 in a cell is bound to Tap42, and this is almost exclusively the TOR-responsive 
fraction. What the remainder of Sit4 is doing in the cell, and how phosphatase molecules 
are “selected” by Tap42, remains to be seen.
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Figure 1-5. The activation of Tap42-associated phosphatases in response to 
TORC1 inhibition. 
Cartoon schematic describing the sequence of events culminating in Tap42-associated 
phosphatase activation as a cell transitions from a nutrient complete environment (A) to 
an amino acid deficient one (B and C). Active signaling molecules are indicated in green 
while inactive complexes are shown in red. The question mark in (C) denotes a point 
which requires future study. See text for more information.  
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Amino Acid Signaling through TORC1 
 
 In order to sense environmental quality, one of the upstream nutrients TORC1 is 
particularly sensitive to is nitrogen, typically in the form of free amino acids. The quality 
of a nitrogen source is defined by its ability to promote glutamine accumulation. These 
catabolites must fuel the equilibrium reactions which maintain cellular levels of α-
ketoglutarate, ammonia, glutamine and glutamate. The mechanism through which 
TORC1 responds to fluctuations in nitrogen donor quality and amino acid availability is 
only now being delineated, and yet there is already a striking level of similarity between 
yeast and mammals, as described below.   
 
 
Yeast 
 
 In yeast, the major amino acid sensing node is the EGO complex, consisting of 
the structural subunit Ego1, the newly discovered Ego2, a homodimer of Ego3, and the 
Rag GTPases Gtr1 and Gtr2 [61, 114, 115]. The active conformation of the Rag GTPases 
includes GTP-bound Gtr1 and GDP-bound Gtr2. When amino acids are not limiting, the 
guanine nucleotide exchange factor (GEF) activity of Vam6 is activated, which 
subsequently inhibits the Gtr1-targeted GTPase activating protein (GAP) function of the 
SEACIT complex [49, 116]. Concurrently, activity of the recently discovered Gtr2 GAP, 
Lst4-Lst7, is promoted and when combined with the effects of SEACIT inhibition, results 
in the active Gtr1(GTP)-Gtr2(GDP) configuration [117]. This stabilizes the association 
between EGO and the TORC1 subunits Kog1 and Tco89, leading to activation of the 
TORC1 complex [49, 61, 114, 118].  
 
 
Mammals 
 
 The lysosome is the critical amino acid sensing organelle in mammals, and 
functionally, it is quite similar to the yeast vacuole. The Ragulator complex resides on the 
lysosomal surface and is analogous to the EGO complex found in yeast. Ragulator 
consists of a scaffolding subunit p18 (LAMTOR1, analogous to Ego1), a heterodimer of 
p14 and MP1 (LAMTOR2 and LAMTOR3, analogous to Ego3), and a heterodimer of 
C7orf59 and HBXIP (LAMTOR4 and LAMTOR5, suggested analogy to EGO2) [119-
123]. Additionally, Ragulator is associated with a heterologous pair of Rag GTPases, 
RagA/B and RagC/D. Regulation of these GTPases occurs in response to nucleotide 
loading, very similar to how Gtr1 and Gtr2 function in yeast. Specifically, when amino 
acids levels are sufficient, Ragulator’s intrinsic RagA/B GEF activity is stimulated by the 
v-ATPase, the RagA/B GAP activity of GATOR1 is diminished, and the RagC/D GAP 
activity of FLCN-FNIP1/2 is activated [123-126]. These events coordinate the active 
nucleotide configuration of the Rag GTPases, with GTP-bound RagA/B and GDP-bound 
RagC/D [127]. In their active conformation, the Rag GTPases function to bridge 
mTORC1 and the lysosome [128]. At the lysosomal surface, mTORC1 is activated via 
interactions with the Rheb1 GTPase [129]. A recent study from Fawal et al. suggests that 
in addition to amino acid dependent spatial regulation of mTORC1, there may be a 
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mechanism in place which also links amino acid availability and the cellular distribution 
of Rheb1 [130]. The group identified microspherule protein 1 (MCRS1) as a critical 
mediator of Rheb lysosomal localization and nucleotide loading status in an amino acid-
dependent fashion. Until recently, it was unclear how cells relayed amino acid levels in 
the lysosomal lumen to the Ragulator complex and mTORC1. A number of groups now 
report that the transmembrane solute carrier SLC38A9 is able to monitor amino acid 
accumulation in the lysosomal lumen and interact with the Ragulator complex in an 
amino acid-dependent fashion [131-133]. In total, activation of mTORC1 requires 
significant spatial and temporal coordination, as the Rags are responsible for promoting 
mTORC1’s localization to the lysosome, MCRS1 is responsible for bringing active Rheb 
to the lysosome, and Rheb is responsible for activation of mTORC1 [128]. 
  
 The oncoprotein Rab1A was also recently identified as an amino acid responsive 
activator of mTORC1, but interestingly, it does so independently of the Rag GTPases 
[134]. Rab1A is overexpressed in colorectal cancer and this correlates with tumor 
invasiveness and an overall poor prognosis. High levels of Rab1A means cells are far 
more sensitive to amino acid starvation. In fact, they require high levels to continue 
growing and are said to be nitrogen “addicted”. Altogether, this suggests that 
deregulation of amino acid signaling through mTORC1 can contribute to cellular 
dysfunction and organismal disease. 
 
 
TORC1’s Nuclear Functions 
 
 Given the array of environmental stimuli that influence TORC1 activity, and the 
role TORC1 plays in regulating the cell cycle, gene expression and anabolism, the 
complex is uniquely qualified to serve as a link between nuclear processes and nutrient 
availability. Yet to date, most of what is known about TORC1 is in reference to its 
cytoplasmic functions. This is due in large part to a number of publications in both yeast 
and mammalian cell culture models that suggest the majority of TORC1 resides in the 
cytoplasm, and more specifically, at the vacuole/lysosomal compartments [119, 124, 128, 
135]. And while this view represents the historical understanding of TORC1, it fails to 
account for an emerging body of literature which has identified a role for nuclear-
localized Tor kinase, and even components of TORC1, in transcriptional regulation [136-
139]. There is still a considerable amount of research to be done in order to fully 
understand the nuclear functions of Tor kinases. However, the fact that TORC1 can be 
found in the nucleus, and even at specific gene promoters, means that the complex may 
directly bridge environmental status to cell cycle regulation, gene transcription, and/or 
the epigenome. 
 
 
Effects on ribosomal DNA transcription 
    
 Traditionally, there have been two levels at which TORC1 can affect 
transcription, particularly as it relates to ribosome biogenesis. The first involves 
regulation of RNA polymerase I (RNAPI) promoter binding through phosphorylation of 
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Rrn3 (TIF-IA in mammals); an integral transcription factor which localizes to the rDNA 
to recruit RNAPI. At the rDNA, RNAPI is responsible for production of the 35S pre-
ribosomal RNA (rRNA), which is ultimately co-transcriptionally processed into the 25S, 
18S, and 5.8S rRNAs. These rRNAs are critical components of the ribosome machinery. 
Inhibition of TORC1 results in a rapid redistribution of RNAPI from the nucleus to the 
nucleoplasm, as well as enhanced Rpd3 binding to the rDNA [140, 141]. Subsequent 
Rpd3-dependent histone H4 lysine 5 and 12 deacetylation promotes condensin complex 
association, which compacts and stabilizes chromatin leading to decreased nucleolar 
volume [140, 142]. There is controversy in the field as to whether the RNAPI 
redistribution is a consequence of Rpd3-dependent transcriptional repression (via 
deacetylation), or is independent of Rpd3 [140, 143]. TORC1 has also been identified as 
a regulator of RNAPII-dependent RP gene expression, and RNAPIII-dependent 5S rRNA 
and tRNA production. It does so via Sch9-dependent phosphorylation of RP transcription 
factors such as Rtg1/3, Gln3, Tod6 and Dot6, or the RNAPIII negative regulator Maf1 
[75, 86, 144-149]. These phosphorylation events mediate both the activity and 
localization of these factors as was mentioned in the previous sections. 
 
 
TORC1, sirtuins, and the epigenetic modification of histones  
 
 Besides the direct mediation of polymerase function and transcription factor 
localization, there seems to be a poorly characterized third layer of TORC1-dependent 
effects on gene expression that involves regulation of chromatin structure through histone 
post-translational modifications [12, 66, 150-152]. Work from our lab shows that direct 
inhibition of yeast TORC1, either through subunit deletion or rapamycin treatment, 
results in globally diminished histone H3 lysine K56 acetylation (H3K56ac); a mark tied 
to DNA repair, maintenance of rDNA copy number, and overall genomic stability [66, 
153, 154]. We also demonstrate that TORC1-regulated H3K56ac influences RNAPI 
binding to the 35S rDNA, as well as binding of the key Pol I transcriptional regulators 
Hmo1 and the SSU processome [66]. Although the exact mechanism linking TORC1 to 
this acetyl mark is currently unknown, our previous data suggests that regulation of the 
sirtuin histone deacetylases may be involved. Specifically, deletion of HST3 or HST4 is 
sufficient to restore H3K56ac in a TORC1 mutant [66]. 
 
 The sirtuins are a conserved, NAD+-dependent family of histone deacetylases that 
in yeast includes Hst1, Hst2, Hst3, Hst4 and Sir2 (summarized in Table 1-1). They are 
sometimes referred to as class III histone deacetylases. Interestingly, despite their varied 
functions, all seven human sirtuins (SIRT1-7) most closely resemble yeast Sir2 according 
to standard BLAST alignment [155]. The relationship between sirtuins and TORC1 is 
particularly interesting as both have been heavily discussed as regulators of aging [70, 81, 
156]. As mentioned previously, inhibition of TORC1 with rapamycin or CR extends 
lifespan and, fascinatingly, activation of sirtuin function with resveratrol mimics these 
effects [70, 157-159]. As a whole, the sirtuins’ best characterized role in the cell is 
transcriptional silencing, particularly at the silent mating type loci, telomeres and rDNA. 
To date, there are only a few characterized substrates for the yeast sirtuins, including the 
non-histone protein Ifh1 (deacetylated by Hst1 and Sir2), and the histone residues 
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Table 1-1. Summary of sirtuin histone deacetylase localization and substrate 
specificity in yeast. 
 
HDAC Subcellular Localization 
Genomic 
Localization 
Histone 
Substrates 
Non-Histone 
Substrates 
Hst1 Primarily  
Nuclear [160]  
Telomeric repeats, 
tRNA genes, 
Pol-II transcribed 
genes [161] 
 
H3K4Ac [162] Ifh1 [163] 
Hst2 Primarily 
Cytoplasmic 
(shuttled out  
of nucleus [160, 
164, 165]) 
Telomeric repeats, 
rDNA, Silent mating 
type loci, Stationary 
phase granules [165-
167] 
 
H4K16Ac [168]  
Hst3 Primarily  
Nuclear [160] 
Telomeric repeats, 
rDNA, Silent 
chromatin, 
Sites of DNA repair 
[153, 169-173] 
 
H3K56Ac [154, 174, 
175] 
 
Hst4 Primarily  
Nuclear 
(shuttles to 
mitochondria 
[160, 176]) 
Telomeric repeats, 
rDNA, Silent 
chromatin, 
Sites of DNA repair 
[153, 169-173] 
 
H3K56Ac [154, 174, 
175] 
 
Sir2 Primarily  
Nuclear [160] 
Telomeric repeats, 
rDNA, Silent mating 
type loci [13, 161, 172, 
173] 
H3K4Ac [162] 
H3K9Ac [177], 
H4K16Ac [177, 178] 
Ifh1 [163] 
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H3K4ac (deacetylated by Hst1 and Sir2), H3K9ac (deacetylated by Sir2), H3K56ac 
(deacetylated by Hst3 and Hst4), and H4K16ac (deacetylated by Hst2 and Sir2) [154, 
162, 163, 168, 170, 174, 175, 177, 178]. The sirtuins are primarily found in the nucleus, 
with two exceptions; Hst2 is actively shuttled from the nucleus to the cytoplasm in a 
Crm1-dependent fashion due to the presence of a nuclear export signal [164], while Hst4 
is known to move from the cytoplasm to the mitochondria in response to biotin starvation 
[176]. A similar shuttling phenomena is also seen with the mammalian sirtuins, SIRT1 
and SIRT2 (see Table 1-2).  
 
 Hst3 and Hst4 are unique in that they appear to be regulated in a cell-cycle 
dependent fashion. The protein levels of Hst3 fluctuate throughout the cell-cycle in 
response to Mec1- or Cdk1-dependent phosphorylation, which promotes SCFCdc4-
dependent polyubiquitination and degradation via the proteasome [179, 180]. A high-
throughput screen designed to identify phosphoproteins that bind the SCFCdc4 ubiquitin 
ligase determined that Hst4 may be regulated in a similar fashion [181]. Importantly, the 
phosphatase that opposes these SCFCdc4 binding phosphomarks is still unknown.  
 
 Of all the sirtuins, the best characterized is Sir2. Its role in cellular aging and CR-
mediated lifespan extension has been investigated over the last decade, with many groups 
linking deletion of SIR2 to rDNA instability and yeast senescence [13, 69, 182, 183]. 
Specifically, inhibition of yeast TORC1 promotes rDNA association of Sir2, possibly in 
concert with the RENT complex, ultimately resulting in a hypoacetylated and deactivated 
rDNA chromatin architecture [13]. Sir2-dependent rDNA deacetylation enhances 
stability, suppresses extra-ribosomal circle formation, and significantly extends yeast 
replicative lifespan [13].  
 
 There are also noted interactions between mTORC1 and sirtuins in mammals. For 
example, SIRT4 gene expression is tied directly into glutamine metabolism via mTORC1 
[184]. When amino acids are limiting, mTORC1 promotes proteasomal destruction of 
CREB2, a transcriptional regulator of SIRT4, which ultimately results in a decrease in 
SIRT4 levels. In this way, mTORC1 can modulate activation of the glutamine 
dehydrogenase promoter, a critical regulatory step in the production of key TCA cycle 
metabolites. There are a number of cancers that display aberrant SIRT4 expression, 
suggesting that dysfunctional mTORC1 activity may promote transformation through 
altered cell metabolism at the level of chromatin regulation. A second mammalian sirtuin, 
SIRT1, has been identified as a negative regulator of mTORC1 via interactions with the 
upstream TSC complex [185]. Interestingly, SIRT1 overexpression can complement loss 
of Sir2 at the level of rDNA stabilization, and SIRT6 (like Hst3 and Hst4) deacetylates 
H3K56ac, suggesting there is evolutionary conservation of function of these enzymes 
[177, 186].  
 
 A number of fascinating genetic interactions between TORC1 and histone H3 
suggest signaling through the TORC1 pathway, or TORC1-mediated epigenetic 
modifications, may directly influence other chromatin-based processes. Our laboratory 
screened individual mutants of the majority of residues on the H3 and H4 tails and found 
only one, H3K37, whose maintenance is indispensable in response to decreased TORC1  
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Table 1-2. Summary of sirtuin histone deacetylase localization and specificity in 
mammals. 
 
HDAC Subcellular Localization Histone Substrates 
Non-Histone 
Substrates 
SIRT1 Actively shuttles between 
nucleus and cytoplasm,          
primarily nuclear [187, 188] 
H3K9Ac [177], 
H4K16Ac [177, 189, 
190], H3K9me2 [191] 
(indirect) 
LC3 [192, 193], Atg5/7/8 
[194], p300 [195], MOF 
[196], Tip60 [197, 198], p53 
[199-201],  FOXO factors 
[202, 203], NFκB [204], c-
Myc [205], HIF-1α [206-
208],         PGC-1α [209], 
LKB1 [210], Ku70 [211], 
PARP1 [212, 213]  
 
SIRT2 Actively shuttles between 
nucleus and cytoplasm,  
primarily cytoplasmic except 
during G2-M [187, 214, 215] 
 
H4K16Ac [168] p53 [216], FOXO3a [217, 
218] 
SIRT3 Mitochondrial,  
small nuclear fraction at 
stress response genes [187, 219-
221] 
 
H4K16Ac [222] 
(indirect) 
AceCS2 [223, 224],    
ALDH2 [225],  
SdhA [226, 227], Ku70 [228] 
 
SIRT4 Mitochondrial [187, 221, 229]  GDH [230] 
 
SIRT5 Mitochondrial [187, 221]  CPS1 [231, 232] 
 
SIRT6 Nuclear [187, 233] H3K9Ac [234-236], 
H3K18Ac [237], 
H3K56Ac [236] 
 
CtIP [238] 
SIRT7 Nucleolar [187, 239] H3K18Ac [240]  
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activity [152]. These dramatic phenotypes are independent of glucose-dependent 
Ras/PKA signaling, suggesting the linkage between TORC1 and H3K37 is specific. 
Interestingly, because TORC1 is also sensitive to glucose, this may indicate that H3K37 
is more strongly coupled to the amino acid sensing arm of TORC1. Mutation of this 
lysine to an alanine (H3K37A) results in a dramatic redistribution of high mobility group 
proteins (HMGs), including Nhp10, from chromatin to the cytoplasm accompanied by 
accelerated chronological aging. This is particularly fascinating considering that Nhp10 is 
a member of the INO80 chromatin remodeler, and TORC1 has already been shown to 
affect transcription through altered recruitment of histone chaperones and chromatin 
modifying complexes [241, 242]. A number of other remodelers are also anchored to 
chromatin through their HMG-containing subunit, a family of structural proteins that will 
be discussed further below.  
 
 
High-Mobility Group Proteins: “The Architectural Transcription Factors” 
 
 HMGs are highly charged, extremely abundant, and the second most common 
protein found on chromatin besides the histones. There are three families of HMGs in 
mammals: HMGA, HMGB and HMGN. All three compete with H1 for binding to the 
linker DNA, and weakening of this H1 association results in decreased chromatin 
compaction [243-245]. Because yeast do not have obvious HMGA and HMGN factors, 
the HMGB class will be our main focus. HMGB family members bind the minor groove 
of B-form DNA with relatively low sequence specificity to introduce sharp bends or 
kinks into the strand. They are particularly enriched at the nucleosomes flanking 
transcriptional start sites, but can also be found at four way DNA junctions and 
significantly under twisted DNA [246]. The effect HMGBs have on gene expression 
(stimulatory or inhibitory) is often context dependent. Some data suggest the HMGBs 
simply distort DNA to promote incorporation of the transcriptional machinery, while 
others argue that in addition to bending DNA, HMGBs may also bridge associations of 
basal transcription factors (ex. TBP) with the transcriptional machinery [247-250].  
 
 The best-characterized mammalian HMGB member is the prototypical HMGB1. 
It has been identified as the most mobile of all nuclear proteins, as it can traverse the 
entire nuclear compartment in just over a second [251]. Interestingly, during cellular 
apoptosis, HMGB1 movement in the nucleus ceases and it remains anchored to 
chromatin, though the mechanism regulating this process is unknown [251]. This effect is 
believed to promote severely under-acetylated heterochromatic DNA. In vitro 
nucleosome binding studies, conducted with an array of HMGB1 truncation mutants, 
identified a specific C-terminal acidic sequence of HMGB1 that is necessary to promote 
transcription [252]. Crosslinking experiments show that the acidic region functions to 
enable HMGB1 to associate with the nucleosome via the histone tails, and specifically 
H3. Kawase et al. followed up on this work, utilizing mass spectrometry to perform a 
characterization of the association between HMGB1 and the nucleosome [253]. They 
reported that the acidic C-terminal tail of HMGB1 makes direct contact with H3K36 and 
H3K37 on H3, suggesting these sites play a vital role in securing HMGB1 to chromatin. 
HMGB1 is released from chromatin during necrosis to promote the innate immune 
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response by binding the Toll-like and RAGE receptors on immune cells [251, 254]. 
Association of HMGB1 with its RAGE receptor in tumor cell mitochondria is essential 
for optimal mitochondrial function, enhanced ATP production, and the dysfunctional 
bioenergetics observed in tumor microenvironments [255]. The nuclear to cytoplasmic 
translocation, and subsequent extracellular secretion, of HMGB proteins in senescent 
cells also promotes the senescence-associated secretory phenotype (SASP), which 
increases cancer risk in aging tissues [256]. Considering all of the evidence described 
above, deregulation of HMGB chromatin binding in mammals, particularly as cells age, 
has the potential to be transformative. 
 
 Yeast HMGBs fall into two general categories based on the number and structure 
of their HMG domains: a single sequence-specific HMG box, or two relatively sequence-
independent HMG boxes. There are seven known HMGBs in yeast, Hmo1, Nhp6a/b, 
Nhp10, Ixr1 [257-259], Rox1 [258, 260-262] and Abf2 [263-266]. We will elaborate on 
the function of the HMGs that are particularly relevant to this work; Hmo1, Nhp6a/b and 
Nhp10.  
 
 Hmo1 is probably the best-characterized member of the yeast HMGB family. 
Hmo1 is exclusively nuclear and organized into three domains, including a classical 
HMG box required for DNA binding and bending (“HMG Box B”), a non-traditional 
HMG box whose function is controversial (“HMG Box A”), and a lysine-rich C-terminal 
nucleolar targeting sequence that also contributes to DNA binding and bending [267, 
268]. The HMG boxes can interact with one and other, and HMG box A is also able to 
associate with Hmo1’s C-terminal tail. Hmo1 chromatin binding promotes compaction, 
the introduction of DNA loops or bends, and SWI/SNF- and ISWIa-dependent chromatin 
remodeling [267, 269, 270]. Hmo1 is involved heavily in ribosome biogenesis, an 
anabolic process significantly regulated by TORC1 (discussed previously). It is highly 
enriched in the nucleolus (nucleolar/nucleoplasmic interface) on active rDNA, and also 
localizes to the promoter of the RP genes [66, 271-274]. An elegant complementation 
study by Albert et al. identified Hmo1 as an rDNA binding component of yeast Pol I 
[275]. The authors also demonstrated that Hmo1 has a robust genetic interaction with 
Rpa49, suggesting involvement in Pol I initiation. 
 
 Nhp6a and Nhp6b are functionally redundant HMG family members, although 
Nhp6a is expressed at much higher levels in the cell. They are homologous to 
mammalian HMGB1/2, and play a significant role in chromatin remodeling [276, 277]. 
Nhp6a contributes to the recruitment of the FACT histone chaperone complex, which 
promotes a chromatin state permissive for transcription, replication, and repair [278-281]. 
Nhp6a also enhances the nucleosome sliding ability of the SWI/SNF ATP-dependent 
chromatin-remodeling complex [269]. In vivo studies with Nhp6a find that even in the 
absence of its acidic domain, chromatin context is still a key determinant of genome-wide 
binding [279, 282]. Given these interactions with well-characterized mediators of 
chromatin structure, aberrant Nhp6a/b localization or abundance is certain to impact gene 
expression patterns and overall cellular function. And finally, similar to the mammalian 
HMGB1 [251, 254], the nuclear to cytoplasmic translocation of Nhp6A is a hallmark of 
necrosis suggested to occur as a consequence of chronological aging [283].  
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 Nhp10 is somewhat unique as it is the only HMGB known to associate with the 
INO80 ATP-dependent chromatin remodeling complex [284]. Nhp10 functions in INO80 
to bridge the remodeler’s interaction with phosphoH2A.Z at double strand breaks, and 
also to protect DNA ends from exonucleatic cleavage at the break site [284-287]. 
Sekiguchi et al. find that in strains where INO80’s catalytic subunit has been mutated, 
loss of EGO function is synthetically lethal, implicating INO80 in TORC1-dependent 
chromatin regulation [288]. As described above, Nhp10 chromatin binding also appears 
to be linked with TORC1 activity via the H3K37 residue, though the exact nature of this 
relationship is currently unclear [152].  
 
 
Tor Dysfunction and Age-Related Pathologies 
 
 Aging is a very complex process which remains poorly understood at the 
molecular, cellular, and organismal level. Studies over the past several decades have 
identified significant overlap between lifestyle, environmental factors, and epigenetics in 
determining the long-term health and viability of an organism. Fascinatingly, TORC1 
may lie at the center of all three of these. It is clear that as an organism ages, a number of 
pathologies become more prevalent, including cardiovascular disease, cancer, diabetes 
and dementia. These diseases are all believed to be driven at some level by mTORC1 
hyperfunction, which is itself a result of aging [289]. But it remains unclear as to why 
overactive mTORC1 has such a profound effect on cellular physiology and longevity.  
 
 The apparent association of TORC1, sirtuins and chromatin dynamics is 
intriguing as they have all been heavily cited as regulators of aging. Yet to our 
knowledge, there is very minimal mechanistic understanding to link all three. Inhibition 
of TORC1 with rapamycin or CR extends lifespan [68, 70-74, 290], activation of sirtuin 
function through treatment with resveratrol mimics these effects [67, 157-159, 291], and 
deletion of sirtuins dramatically reduces lifespan [170, 292]. This fact is incredibly 
important because we will present data showing that TORC1 inhibition promotes sirtuin 
function and histone deacetylation through a novel subcellular accumulation and 
stabilization mechanism. Such a relationship could also explain why there is controversy 
regarding which target (mTor vs. sirtuins) would be best to pursue in slowing or 
reversing cellular aging (as reviewed by Sinclair) [290].  
 
 The majority of tissues in the body consist of a large population of post-mitotic, 
fully-differentiated cells, and a smaller stem cell niche tasked with replenishing and 
maintaining the population over time. Classical aging phenotypes are most often 
attributed to cellular chronological aging, which is marked by an overall decline in cell 
health and function, culminating in physiological defects on the organismal scale. Recent 
evidence in skeletal muscle and the brain suggests that the longevity and viability of both 
the long-lived post-mitotic populations, as well as their stem cell niches, depends on 
sustained maintenance of chromatin as cells mature/age. Jurk et al. demonstrate that upon 
proliferative cessation, mature neurons enter a senescent-like state marked by 
heterochromatinization, elevated ROS production, persistent DNA damage, and other 
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traditional indicators of the senescence-associated secretory phenotype [293]. These 
effects become more prominent and deleterious with age but can be partially reversed by 
CR. And although the authors do not address the nature of this effect, it does suggest the 
possibility that nutrient responsive TORC1 function may contribute to the development 
of age-related senescence. We are particular fascinated with the chromatin effects 
observed in these cells, because it is now known that chromatin states in non-mitotic 
neurons are not nearly as static as they once seemed [294-297]. Gong et al. show that in 
aging mouse brains, there is a notable shift in the epigenetic landscape, including the 
acetylation and methylation of H3/H4, and many of these same modifications are 
responsive to CR or rapamycin treatment [298]. Liu et al. report that maintenance of 
quiescence in skeletal muscle stem cells correlates to a unique epigenetic signature which 
degrades with age [299]. Corruption of these signatures, specifically a genome-wide 
overrepresentation of H3K27me3, results in heterochromatin accumulation which the 
authors speculate contributes to an observed loss of stem cell function with age.  
 
 The above demonstrates how chromatin deregulation contributes to loss of 
function in vital cell populations, which ultimately results in organismal aging. It is the 
goal of this dissertation to characterize the mechanism by which TORC1 activity affects 
these processes, and to evaluate their potential contribution to organismal viability and 
longevity. In other words, to functionally understand the intersection between an 
organism’s environment, lifestyle, and epigenome as it relates to health and longevity. 
The project presented below is guided by the following Specific Aims:  
 
 (1) Define the contribution of TORC1 signaling to the regulation of histone 
 acetylation modifications and elucidate the mechanisms involved.  
 
 (2) Determine the impact that TORC1-regulated histone acetylation has on 
 cellular functions. 
 
 (3) Define the role of the poorly-understood TORC1 subunit Tco89 in TORC1 
 signaling and epigenetic regulation. 
 
Addressing these Specific Aims will provide significant insight into TORC1-dependent 
coordination of epigenetic mechanisms under normal biological conditions, while also 
identifying how TORC1 dysfunction and epigenetic corruption may contribute to disease 
mechanisms on an organismal scale. 
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CHAPTER 2.    MATERIALS AND METHODOLOGY 
 
 
Yeast Strains, Plasmids, and Culture Conditions 
 
 All of the yeast strains and plasmids used in this work are described in Tables 
A-1 and A-2 (in Appendix A), respectively. Strains constructed in our lab, including 
gene deletions and epitope tags, were made using PCR-generated targeting cassettes as 
previously described [300]. Unless otherwise stated, cells were grown in YPD (1% yeast 
extract, 2% peptone, and 2% dextrose) at 30° C with shaking. For experiments conducted 
in synthetic complete media, dropout mix was incorporated and supplemented with the 
appropriate amino acids to compensate for the auxotrophy of the strains. All media 
components were purchased from US Biologicals or Research Products International 
(RPI). Phos-tag was purchased from Wako Chem. Rapamycin, nicotinamide, sodium 
butyrate, trichostatin A, L-methionine sulfoximine (MSX), 2-(N-morpholino) 
ethanesulfonic acid (MES), and caffeine were purchased from either Fisher Scientific or 
Sigma-Aldrich. Galactose was purchased from MP Biomedical. The concentrations of 
these reagents are noted in the text.  
 
 Cloning primers for Tco89 fragmentation and Tco89/Sit4 complementation 
studies were designed as discussed in the text and as previously described [300]. The 
open reading frames of TCO89 and SIT4 were cloned as C-terminal mono-FLAG fusions 
into the BamHI/XbaI (Tco89FL and fragments) or BamHI/EcoRI (Sit4FL) restriction 
sites of the pRS416ADH plasmid, which contains an ADH1 promoter and CYC1 
terminator [301]. PSI/PRED prediction software was used to avoid disruption of any 
potential secondary amino acid structure (discussed in Chapter 5) [302]. See Table A-2 
for more information. 
 
 
Antibodies and Stains 
 
 Antibodies used in this work were obtained from the following; α-RPS6 (Abcam), 
α-phosphoS6 (Cell Signaling), α-FLAG (Stratagene), goat α-rabbit HRP conjugated 
secondary (Jackson), α-Myc 4A6 (Millipore), α-HA and α-Myc A14 (Santa Cruz), 
G6PDH (Sigma), α-FLAG (Thermo), goat α-rabbit FITC-conjugated secondary 
(Rockland). Histone antibodies were all obtained from Active Motif. IgA- and IgG-
conjugated beads for immunoprecipitation were from Santa Cruz. For live cell work, 
5(6)-Carboxyfluorescein diacetate (CFDA) vacuolar stain was obtained from Invitrogen, 
dihydroethidium (DHE) from Fisher, and Hoechst nuclear stain from Life Technologies. 
For fixed cells, the Vectashield mounting media containing DAPI was purchased from 
Vector Labs. The apoptosis and necrosis staining experiments were conducted using an 
AnnexinV-FITC apoptosis kit from Clontech, and YO-PRO-1, propidium iodide (PI) and 
SYTOX from Life Technologies.  
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Western Blotting and Statistical Analysis 
 
 Cells were grown to log phase (OD600 ≈0.8) in the indicated media as described 
above prior to treatment with drug (rapamycin or MSX) or galactose (2% final 
concentration), unless noted. Typically, cultures were set up to double 3 to 4 times before 
reaching this OD, ensuring that the majority of cells were replicatively young and 
metabolically active. Cells were then transferred to 50 mL falcon tubes using sterile 
technique, pelleted in a tabletop centrifuge, and frozen at -80°C. Pellets were resuspended 
in pre-chilled cracking buffer (10 mM Tris pH 8.0, 150 mM NaCl, 0.1% Nonidet P-40, 
10% glycerol, 1 mM DTT) with additional phosphatase, histone deacetylase, and protease 
inhibitors. Glass beads were added to each tube, and the cells were lysed using a cold-
room bead beater (3x 30 sec pulse with 3 min on ice in-between). Supernate was clarified 
at 4°C and stored at -80°C. Extract concentrations were determined using a traditional 
Bradford assay, and 35 μg samples were resolved by SDS-PAGE and transferred to 
PVDF membrane. In the case of samples subjected to SDS-PAGE with Phos-tag additive 
(50 μM), the included manufacturer’s instructions were followed. Membranes were 
probed overnight at 4°C with primary Ab. The blots were washed in TBST (10% TBS, 
0.1% tween) for at least an hour with buffer replacement every 15 minutes. The blots 
were then incubated in secondary Ab for between 2 and 4 hours before developing using 
autoradiography. Films were scanned and analyzed by ImageJ where denoted. For 
determining significance, we used a two-tailed, unequal variance, pairwise Student’s t-
test. *p<0.05, **p<0.01, ***p<0.001. 
 
 
Spotting Assays 
 
 Cells were grown overnight at 30°C with shaking to saturation. OD600 readings 
were taken and equivalent numbers of cells were aliquoted into column A of a sterile 96-
well culture plate (see formulas below). The volumes in column A were made up to 200 
μL with sterile water. 
 
???????? ?
???
???????????????????????????
????????????????????????? ?? ? ??? ? ???????? 
 
 Five-fold serial dilutions were then performed in which 40 μL of column A were 
transferred into 160 μL of water in column B and so forth. Cells were spotted to plate 
media and incubated as noted. Images were taken daily for 5-7 days using a UVP Digital 
Imaging System.  
 
 
RT-qPCR 
 
 cDNA was synthesized from DNase I treated cellular RNA using random 
hexamer primers and the ImProm II reverse transcriptase system from Promega. Gene 
specific qPCR was conducted and normalized to the SPT15 housekeeping gene as 
previously described [303]. Primers are available upon request.  
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Indirect Immunofluorescence Confocal Microscopy 
 
 For studies regarding sirtuin localization, the following technique was utilized. 
First, cells were grown to log phase and treated as indicated. The cells were then fixed 
with 37% formaldehyde, pelleted at 800xg for 4 minutes, and washed twice with 4 mL of 
0.1 M potassium phosphate buffer (K2HPO4, pH=6.5) and once with 4 mL P solution (1.2 
M sorbitol, 0.1 M K2HPO4, pH=6.5). Pellets were then gently resuspended in 1 mL P 
solution and incubated at room temperature with 15 μL zymolase (15 mg/mL in P 
solution) and 5 μL β-mercaptoethanol for 25 minutes. Cell wall digestion 
(spheroplasting) was confirmed using a phase contrast microscope. After spheroplasting, 
cells were gently pelleted and resuspended in 150 μL of P solution. The resulting 
suspension was aliquoted to a poly-lysine coated slide and cells were allowed to settle for 
20 minutes prior to blocking (8% bovine serum albumin/PBS/0.5% Tween 20). Slides 
were then placed in a humidified chamber and incubated in primary antibody overnight at 
4°C. Following primary incubation, slides were washed four times with blocking 
solution, prior to the addition of fluorophore-conjugated secondary antibody (60 minutes 
at room temperature). From here on slides were protected from light. After the secondary 
incubation, slides were washed four times with blocking solution and twice with PBS. 
Finally, a drop of DAPI-containing Vectashield mounting media was placed on the slides 
and coverslips were positioned and sealed. Samples were imaged with the 63x oil 
Olympus objective on a Zeiss LSM 700 confocal microscope. 
 
 
Direct Immunofluorescence Confocal Microscopy 
 
 For studies measuring HMG localization, cells were grown to log phase in 
duplicate 10 mL cultures and treated as indicated. Treatments often occurred over 60 
minutes, so immediately following addition of drug, the process to image the untreated 
cells began. Untreated cells were spun down, washed with sterile water, transferred to a 
microfuge tube and pelleted. The cells were then resuspended in 100 μL sterile water 
with 2 μL Hoechst and incubated with agitation away from light for 15 minutes. Finally, 
the untreated cells were spun down, resuspended in 10 μL sterile water with 0.5 μL 
Hoechst and cover slipped as quickly as possible to avoid effects the altered nutrient state 
may have on the results. Slides were imaged with the 63x oil Olympus objective on a 
Zeiss LSM 700 confocal microscope. Following the one hour incubation of the treated 
cells, the above steps were repeated.  
 
 
Image Analysis in Zen 2 Blue 
 
 In order to quantitate the subcellular localization of the tagged proteins, images 
taken on the Zeiss LSM 700 were analyzed in the Zen Lite Version 2.0.0 software 
program (blue edition) as previously described [304]. Briefly, using the Spline Contour 
tool, a border was drawn around the outer edge of each cell. Then, a second border was 
drawn around the nucleus. Upon closure of each border, information was provided, 
including the area within the border, and the mean intensity of each channel inside that 
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space. The mean intensity value for the green channel within the nucleus was multiplied 
by the area within the nuclear border to obtain our total nuclear fluorescence intensity 
(TNFI). 
 
???? ? ???????? ??????????????????? ? ?????????????????? 
 
 This calculation was repeated for the values from the outer cell border, providing 
us a value we refer to as the total cellular fluorescence intensity (TCFI).  
 
???? ? ????????? ??????????????????? ? ??????????????????? 
 
 From there, we simply divided the total nuclear intensity by the total cellular 
intensity and multiplied by 100 to get the percentage of our protein of interest that resides 
in the nucleus.  
 
????????? ?
????
????
? ??? 
  
 Analysis fields were chosen at random, with approximately 20-40 cells quantified 
per condition, per independent biological replicate (4-6 replicates). Cells with a cellular 
mean intensity value under 50 units were excluded from calculations as we believe this is 
the threshold of adequate immunostaining.  
 
 
Sirtuin Turnover/Half-Life Analysis 
 
 Cells were grown to log phase in 200 mL YPD flasks. At T0, 50 mL aliquots were 
sterilely sampled from each sample, pelleted, and frozen. Cycloheximide (CHX) was then 
added to each flask at a concentration of 100 μg/mL. 50 mL aliquots were retained as 
described above at the time points indicated. Whole cell extracts (WCEs) were prepped 
and analyzed by α-Myc immunoblot. Films were scanned, quantified with ImageJ, and 
sirtuin signals were normalized to total protein via G6PDH. 
 
 
Apoptosis, Necrosis, DHE and CFDA Assays 
 
 For analysis of apoptosis and necrosis, log phase cells were pelleted, washed 
twice with sterile PBS, and incubated for 20-30 minutes in the respective dyes: PI (50 
μg/mL) and YO-PRO-1 (10 μM). Cells were then transferred to flow cytometry tubes, 
processed on a BD LSRII flow cytometer, and analyzed using FLOWJO V10. DHE (30 
μM) and CFDA (100 μM) staining experiments were identical to the above except for the 
use of the different stains, and the retention of cells for additional confocal analysis.  
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Scoring for Tco89 Fragment Phenotypes 
 
 WT and tco89Δ cells were transformed with control vector or Tco89 N-terminal 
truncation fragments as indicated, grown to saturation, and spotted as detailed previously 
(see “Spotting Assays” section of this chapter). Growth on the spotting plates was scored 
as described by Rizzardi et al. [305]. Briefly, mutants were scored on a scale of -3 to 3, 
with a score of 1 representing an approximate 5-fold difference in growth and a value of 
3 being a 125-fold difference. Strains exhibiting growth defects compared to wild-type 
cells received a negative value, while those with enhanced growth were given a positive 
value. A value of 0 indicates growth essentially equivalent to the control. Scores from at 
least five independent transformations were averaged, and a heat map was constructed in 
Microsoft Excel.  
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CHAPTER 3.    TORC1 FUNCTION MAINTAINS HISTONE ACETYLATION 
BY OPPOSING THE SIT4-DEPENDENT NUCLEAR ACCUMULATION OF 
SIRTUINS1 
 
 
TORC1 Mediates Site-Specific Histone H3 and H4 Acetylation in Response to 
Environmental Stress, Particularly Glutamine Starvation  
 
 Our previous work identified a connection between TORC1 and the control of 
global H3K56ac [66]. We wanted to determine whether this effect was unique to 
H3K56ac, or if TORC1 also regulated other acetylation states on the histone H3/H4 tails. 
To do so, wild-type and tco89Δ cells were grown to log phase and wild-type cells were 
either mock or rapamycin treated (300 nM) for 60 minutes. The concentration and length 
of rapamycin treatments selected were confirmed to diminish TORC1 activity by 
phosphoS6 blot (Figure B-1 in Appendix B). WCEs prepared from these samples were 
screened for alterations to distinct histone acetylation states by immunoblotting (IB) with 
the indicated antibodies (Figure 3-1A). Films were scanned and analyzed by ImageJ, and 
relative histone acetylation was calculated by normalizing to total H3 with the mock 
treated samples set to 1 (graphed in Figure 3-1B). As shown in Figure 3-1A, TORC1 
inhibition resulted in a dramatic site-specific reduction of acetylation at H3K18 
(H3K18ac), H3K23 (H3K23ac), and H4K12 (H4K12ac), while other acetylation states 
were unaffected. These changes cannot be attributed solely to downregulation of 
transcription-coupled marks as we find that H3K4me3, a histone modification that 
demarcates actively transcribed genes, was unaffected. Loss of these histone 
modifications is unlikely to be explained by indirect consequences of TORC1 inhibition, 
since the acetylation reduction was observed as early as 20 minutes post-rapamycin 
treatment (Figure 3-1C). Furthermore, we demonstrated that exogenous Tco89 
expression in the tco89Δ rescued acetylation, thus confirming that reduction of histone 
acetylation was due solely to the loss of this TORC1 subunit (Figure 3-1D).  
 
 Nitrogen metabolism, described in Chapter 1, is an established activator of 
TORC1 via the vacuolar-localized EGO and v-ATPase complexes. Prior evidence 
suggested carbon metabolism may regulate many of the histone acetylation states 
identified in Figure 3-1A [306]. Therefore, we next compared the impact of these 
nutrient signals on our sites of interest to determine whether the mechanisms which link 
carbon and nitrogen to the epigenome are overlapping, via TORC1, or are distinct. We 
first utilized the glutamine synthetase inhibitor MSX to block glutamine biosynthesis and 
impair nitrogen metabolism (Figure 3-2A). Treatment with 2 mM MSX mimicked the 
decrease in H3K18ac that occurs in response to direct TORC1 inhibition (Figure 3-2B, 
upper panel and graph). We confirmed MSX treatment reduced TORC1 activity by α-
phosphoS6 IB (Figure 3-2B, lower panel). However, changing the quality of the carbon 
source from glucose to non-fermentable carbon (glycerol) failed to affect acetylation in  
                                                 
 
1 Modified with permission from Genetics Society of America. Workman, J.J., H. Chen, and R.N. Laribee, 
Saccharomyces cerevisiae TORC1 Controls Histone Acetylation by Signaling Through the Sit4/PP6 
Phosphatase To Regulate Sirtuin Deacetylase Nuclear Accumulation. Genetics, 2016. 
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Figure 3-1. TORC1 signaling coordinates site-specific lysine acetylation on a 
subset of histone H3 and H4 N-terminal residues. 
A. Wild-type (WT) and tco89Δ cells were grown to log phase and subjected to mock or 
300 nM rapamycin treatment for 60 minutes. Cells were harvested and whole-cell 
extracts (WCEs) were analyzed by immunoblot (IB) with the indicated antibodies. B. 
ImageJ quantification of the results from (A). Data are representative of four or more 
biological replicates. Means and standard deviations (SDs) are provided, and significance 
was determined by pairwise Student’s t-test. *-p<0.05; **-p<0.01; ***-p<0.001. C. As in 
(A), except WT cells were treated with 200 nM rapamycin for 20 minutes. D. WT and 
tco89Δ cells were transformed with control vector (CV) or Tco89-9xMyc expression 
vectors and WCEs were analyzed as in (A). 
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Figure 3-2. TORC1-dependent histone acetylation is responsive to nitrogen, but 
not carbon, limitation. 
A. Schematic showing the step in the glutamine biosynthetic pathway inhibited by MSX 
[307, 308]. B. WT cells were cultured to log phase and then mock treated or treated with 
2 mM MSX for 20 minutes. Cells were harvested and extracts were analyzed by 
immunoblot with the indicated antibodies. ImageJ quantification was conducted, and a 
graphical representation of the mean and SD obtained over 9 independent experiments is 
provided. Significance was determined by pairwise Student’s t-test. ***-p<0.001. C. WT 
and tco89Δ cells were grown to log phase in YP 2% glucose or YP 2% glycerol. Extracts 
were prepared as above and blotted with the indicated antibodies.   
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either the wild-type or the tco89Δ mutant (Figure 3-2C). Given that cells grow more 
slowly in non-fermentable carbon, these findings also ruled out the possibility that the 
acetylation differences in tco89Δ are attributable to the reduced growth rate of this 
mutant. All together, these findings suggest a mechanism in which TORC1 activation, in 
response to nitrogen metabolism, functions to regulate this subset of histone acetyl sites.  
 
 
TORC1 Signals through the Tap42-Sit4 PP6 Phosphatase Complex to Regulate Site-
Specific Histone Acetylation Globally 
 
 After defining the TORC1-regulated histone acetylation states on histones H3 and 
H4, we next wanted to identify which TORC1 downstream effector was responsible for 
mediating these changes. Initially, we examined whether the TORC1-activated Sch9 
kinase contributed to the control of these histone modifications using a series of 
previously described Sch9 expression vectors [80]. These included vectors expressing 
wild-type Sch9 (Sch9WT), a mutant form of Sch9 in which the TORC1 phosphotarget 
sites have been changed to alanines to prevent activation (Sch95A), and another mutant 
Sch9 with those same sites mutated to acidic residues to mimic constitutive TORC1-
dependent Sch9 phosphorylation (Sch92D3E). We first demonstrated that wild-type and 
mutant Sch9 were expressed at relatively similar levels, thus ruling out the possibility that 
these mutations altered protein stability (Figure B-2A). From there, a series of control 
experiments were conducted, beginning with confirmation that in an sch9Δ mutant, 
introduction of the Sch92D3E plasmid enabled growth on non-preferred carbon sources 
and rapamycin (Figure B-2B). We also determined that the mutant plasmid promotes 
Maf1 phosphorylation (a direct substrate of Sch9) regardless of upstream TORC1 activity 
(Figure B-2C) [87]. These findings confirmed that the Sch92D3E mutant did behave 
independently of TORC1 as expected. Introduction of the Sch92D3E mutant into tco89Δ 
failed to rescue acetylation (Figure 3-3A). Furthermore, histone acetylation was not 
reduced in sch9Δ (Figure 3-3B). We conclude that the Sch9 kinase does not function 
downstream of TORC1 to regulate histone acetylation.  
 
 We next investigated whether the other well-characterized downstream TORC1 
effector, Tap42, contributes to the regulation of histone acetylation. TAP42 is an essential 
gene, so we utilized tap42Δ cells possessing a plasmid-based temperature-sensitive (ts) 
Tap42 allele [309]. In Figure 3-4A, we confirmed these three ts strains are indeed acutely 
sensitive to heat stress. We chose to specifically analyze the tap42Δ+tap42-106ts mutant 
as it had the least dramatic temperature sensitivity, which we predicted would limit non-
specific acetylation changes due to impaired viability. Wild-type and tap42-106ts mutant 
cells were grown to log phase at the permissive (25°C) temperature and then shifted to a 
non-permissive condition (30°C) for 1 hour. WCEs were prepared and histone acetylation 
was analyzed by IB. Strikingly, in cells whose TORC1 function was intact, simply 
inactivating Tap42 led to dramatically reduced H3K18ac (Figures 3-4B and C). Even at 
the permissive temperature, there was a specific reduction in TORC1-regulated H3K18ac 
but no effect on H3K9ac, which we know is not responsive to TORC1 (Figure 3-1A). 
These results demonstrate that TORC1 likely signals through a Tap42-associated 
phosphatase to regulate site-specific histone acetylation.  
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Figure 3-3. Regulation of histone acetylation downstream of TORC1 occurs 
independently of the Sch9 kinase. 
A. Wild-type (WT) and tco89Δ cells were transformed with control vector (CV) or 
Sch92D3E-expression vector and grown to log phase in selective media before preparation 
of WCEs. Extracts were analyzed by immunoblot with indicated antibodies. B. WT, 
tco89Δ and sch9Δ cells were grown in YPD and WCEs were prepared. Analysis by 
immunoblot was conducted as indicated. Western blots and histone acetylation averages 
provided are representative of at least three independent experiments, normalized to H3, 
with corresponding WT samples set to 1.  
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Figure 3-4. TORC1-responsive histone acetylation is regulated in a Tap42-
dependent fashion. 
A. tap42Δ cells containing endogenously expressed wild-type Tap42, or various 
temperature sensitive mutants (tap42-11, -109, -106) [309], were grown to saturation, 
five-fold serially diluted, and spotted onto YPD. Plates were cultured at permissive 
(25°C), semi-permissive (30°C), and non-permissive (33°C) temperatures and images 
were taken on day 2. B. Cells from (A) were grown to log phase in liquid culture at 25°C 
before being shifted to 30°C for 1 hour. WCEs were prepared and analyzed by 
immunoblot. C. Quantification of results presented in (B). Data is representative of three 
biological replicates. Means and SDs are provided, and significance was determined by 
pairwise Student’s t-test. **-p<0.01; ***-p<0.001.  
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 The Tap42-associated phosphatases are organized into modular complexes. 
Typically, they are structured such that Tap42 associates with a catalytic subunit, and one 
or more regulatory subunits. To identify which of the phosphatases is required for 
TORC1-regulated acetylation, we screened catalytic mutants of individual Tap42-
associated phosphatase complexes (PPG1/ppg1Δ, PP4/pph3Δ, and PP6/sit4Δ) for the loss 
of rapamycin-induced deacetylation. Since PP2A possesses redundant catalytic subunits 
(Pph21 and Pph22), we instead used a tpd3Δ mutant, which eliminates the PP2A 
regulatory subunit and impairs PP2A function [310]. Notably, only deletion of SIT4, the 
catalytic subunit of the PP6 phosphatase complex, prevented the rapamycin-induced loss 
of H3K18ac (Figure 3-5A). We saw an identical effect on H3K56ac in sit4Δ cells before 
and after rapamycin, strengthening our hypothesis that TORC1 is mediating H3K18ac, 
H3K23ac, H3K56ac and H4K12ac through a conserved mechanism. Importantly, we 
show in Figure 3-5B that transformation of the sit4Δ mutant with a Sit4 expression 
vector was sufficient to restore the rapamycin sensitivity of H3K18ac. Finally, the tco89Δ 
acetylation defect was completely rescued in a sit4Δ tco89Δ combinatorial mutant 
(Figure 3-5C), further demonstrating that TORC1 inhibition promotes loss of histone 
acetylation through the activation of the Sit4 phosphatase.  
 
 The PP6 complex is a heterotrimer consisting of Tap42, Sit4, and one of four 
Sit4-associated regulatory proteins (Saps). To probe whether a particular Sap was 
responsible for Sit4-dependent acetylation repression, we conducted a similar experiment 
as described in Figure 3-5A, except individual Sap deletions were screened. Loss of 
either the Sap4 (sap4Δ) or Sap185 (sap185Δ) subunits led to significant rescue of 
acetylation in rapamycin-treated samples (Figure 3-6). However neither mutant alone 
was sufficient to promote the rapamycin resistance observed in a sit4Δ (Figure 3-5A). 
This suggests that while Sap4 and Sap185 are most likely linked to Sit4-dependent 
regulation of acetylation, there appears to be a degree of functional redundancy between 
the Saps in this regard.  
 
 Sit4’s best-known function in the cell is to regulate the NCR response by 
modulating the phosphorylation, and subsequent localization, of the transcription factors 
Gln3 and Gat1 [75, 113, 145]. When cells are starved for amino acids, Gln3 dissociates 
from the cytoplasmic anchor Ure2 and moves to the nucleus in a Sit4-dependent fashion. 
Nuclear Gln3 then activates transcription of genes required for the utilization of non-
preferred nitrogen sources. Because TORC1 suppression promotes Gln3 nuclear 
localization through Sit4 activation, we probed whether induction of the NCR was 
required for the effect on histone acetylation.  
 
 While loss of Sit4 led to an increase in basal H3K18ac as expected, we found 
surprisingly that deletion of the NCR transcription factors, Gln3 or Gat1, did not result in 
a similar increase in acetylation (Figure 3-7). In support of the above, loss of the 
cytoplasmic anchor Ure2 did not phenocopy the tco89Δ hypoacetylation response 
(Figure 3-7). Taken together, these data suggest that the PP6 protein phosphatase 
complex is responsible for connecting TORC1 to the regulation of histone acetylation and 
that Sit4’s contribution exists outside of the NCR response.   
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Figure 3-5. Sit4-catalyzed PP6 complex activity is required for TORC1-
responsive histone acetylation. 
A. Wild-type (WT), tpd3Δ, ppg1Δ, pph3Δ and sit4Δ cells were grown in YPD to log 
phase before treatment with 300 nM rapamycin for 60 minutes. WCEs were prepared and 
analyzed by immunoblot and ImageJ. B. WT cells transformed with control vector (CV) 
and sit4Δ cells transformed with CV or full-length pSit4-FLAG, were grown to log phase 
in selective media and treated with rapamycin as in (A). Extracts were prepped and 
probed by immunoblot. C. WT, tco89Δ, sit4Δ and tco89Δ sit4Δ were grown to log phase, 
extracts were prepared and blotted as described above. Data are representative of at least 
3 independent replicates, with average histone acetylation values relative to H3 (mock set 
to 1) provided.   
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Figure 3-6. Regulatory subunits of the PP6 phosphatase complex display 
overlapping function in relation to TORC1-responsive histone acetylation. 
As in Figure 3-5A, except mutants are various Sit4-associated protein (SAP) deletions, 
including sap4Δ, sap155Δ, sap185Δ and sap190Δ. Blots are representative of at least 3 
independent replicates and average histone acetylation values relative to H3 (mock set to 
1) are provided. 
 
 
 
 
 
 
Figure 3-7. Sit4-dependent, nitrogen-responsive chromatin modifications are 
separable from the canonical nitrogen catabolite response (NCR) pathway. 
Mutants of the Sit4-mediated NCR stress response, including ure2Δ, gln3Δ and gat1Δ, 
were grown to log phase alongside WT, tco89Δ and sit4Δ, and analyzed by immunoblot 
as indicated. Blots are representative of 3 independent replicates and average histone 
acetylation values relative to H3 (WT set to 1) are provided.   
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TORC1-Responsive Histone Acetylation Is Specifically Regulated by the Sirtuin 
Histone Deacetylases 
 
 In our previous analysis of TORC1-dependent regulation of H3K56ac, we 
reported that loss of either of the sirtuins, Hst3 or Hst4, in a tco89Δ background restored 
acetylation to wild-type levels. This prompted us to investigate whether these newly 
identified TORC1-dependent acetylation states were similarly regulated. Initially, we 
cultured wild-type and tco89Δ cells to log phase and mock treated or treated with 
nicotinamide, a naturally occurring pan-sirtuin inhibitor. Treatment with nicotinamide led 
to an increase in basal H3K18ac in wild-type cells, and also rescued the acetylation 
defect observed in tco89Δ (Figure 3-8A). Strikingly, tco89Δ cells treated with FK866, a 
compound which inhibits sirtuins by blocking NAD+ biosynthesis [311], displayed robust 
restoration of histone acetylation (Figure 3-8B, left panel). The effect of FK866 on 
acetylation in wild-type cells was negligible. A pathway exists in yeast by which active 
TORC1 represses transcription of PNC1, a gene which encodes a nicotinamidase that 
scavenges nicotinamide and shunts it into the NAD+ biosynthetic cycle [67]. This means 
that TORC1 suppression results in both a reduction in the level of sirtuin inhibitor 
(nicotinamide), as well as an increase in sirtuin co-factor availability (NAD+). We next 
asked whether increased PNC1 expression could explain our observed link between 
TORC1 and sirtuin-dependent histone deacetylation. Surprisingly, combining pnc1Δ with 
tco89Δ failed to rescue TORC1-dependent acetylation (Figure 3-8B, right panel).  
 
 To probe whether class I or II histone deacetylases were also contributing to the 
regulation of TORC1-dependent acetylation states, we initially utilized the 
pharmacological inhibitors sodium butyrate and trichostatin A. However, for unknown 
reasons, these compounds failed to provide effective HDAC inhibition (data not shown). 
To circumvent this issue, we combined tco89Δ with a gene deletion of the major class I 
(Rpd3) or class II (Hda1) histone deacetylases to ask whether loss of these HDACs would 
diminish TORC1-dependent deacetylation. While the rpd3Δ and hda1Δ single mutants 
displayed elevated acetylation across our residues of interest, combining these with a 
tco89Δ still led to a significant reduction in acetylation (Figure 3-9, compare 2nd and 4th 
lanes). These results further support the hypothesis that TORC1-dependent histone 
acetylation specifically involves suppression of the sirtuins. To gain a more complete 
understanding as to the contributions of each sirtuin, we created another set of 
combinatorial mutants that paired tco89Δ with individual sirtuin deletions. These strains 
were used to repeat the experiment in Figure 3-9. Strikingly, we found dramatic 
differences in the ability of these sirtuin deletions to rescue site-specific acetylation in 
tco89Δ (Figure 3-10A and B). For example, H3K18 is deacetylated primarily by Hst2, 
Hst3 and Hst4, while H3K23 is solely targeted by Hst4. In all, our findings support the 
idea that active TORC1 promotes acetylation of the H3/H4 N-termini via repression of 
the Sit4/Sap4 PP6 phosphatase and the sirtuin deacetylases, and that this novel 
mechanism does not involve changes in Pnc1 levels or NAD+ biosynthesis.  
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Figure 3-8. TORC1-PP6 catalyzed histone H3/H4 deacetylation is promoted by 
the NAD+-dependent sirtuin family of histone deacetylases. 
A. Wild-type (WT) and tco89Δ cells were grown to log-phase before mock or 25 mM 
nicotinamide (sirtuin inhibitor) treatment for 60 minutes. WCEs were prepared and 
immunoblotted as indicated. Blots are representative of 3 independent replicates and 
average histone acetylation values relative to H3 (WT mock set to 1) are provided.  B. In 
left panel, as in (A) except cells were treated with 500 nM FK866. In right panel, WT, 
tco89Δ, pnc1Δ and tco89Δ pnc1Δ were grown and analyzed by immunoblot as indicated. 
 
 
 
 
 
 
Figure 3-9. Class I and II histone deacetylases are not involved in the observed 
TORC1-PP6 hypoacetylation response. 
WT, rpd3Δ, tco89Δ, tco89Δ rpd3Δ, hda1Δ and tco89Δ hda1Δ were grown to log-phase. 
Extracts were prepped and analyzed by immunoblot. Blots are representative of 4 
independent replicates.  
 39 
 
 
Figure 3-10. TORC1-responsive histone acetylation is modulated by a subset of 
sirtuin histone deacetylases in a site-specific fashion. 
A. Combinatorial tco89Δ sirtuin gene deletion mutants were grown and analyzed by 
immunoblot as indicated. B. ImageJ quantification of data shown in (A). Data are 
representative of at least four biological replicates. Means and SDs are provided, and 
significance was determined by pairwise Student’s T-test. *-p<0.05; **-p<0.01; ***-
p<0.001.   
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Sit4 Activation Downstream of TORC1 Inhibition Promotes Hst4 Stabilization 
 
 Mammalian mTORC1 activity was previously shown to regulate glutamine 
metabolism and TCA cycle replenishment by transcriptional suppression of SIRT4 [184]. 
We speculated that TORC1 inhibition in yeast might function similarly by promoting 
deacetylation through an increase in sirtuin expression. To address this, we epitope-
tagged the sirtuin genomic loci with a 9xMyc epitope in both WT and tco89Δ cells. Cells 
were grown, WCEs prepared, and expression was analyzed by immunoblot. We observed 
dramatic increases in Hst4 and Sir2 protein expression in the tco89Δ mutants relative to 
wild-type cells (Figure 3-11A). Given that we previously identified Hst4 as the only 
sirtuin able to control all of the TORC1-dependent acetylation modifications (Figure 
3-10), we selected it for further examination across a variety of TORC1 inhibitory 
conditions. Short-term rapamycin and MSX treatment had no effect on Hst4 levels in 
wild-type cells; however, both tco89Δ and 60-minute exposure to rapamycin led to 
elevated Hst4 expression compared to the mock-treated wild-type cells (Figure 3-11B). 
Considering that 20-minute TORC1 inhibition was sufficient to reduce histone 
acetylation (Figures 3-1C, 3-2B), we were surprised to find that Hst4 levels did not 
significantly increase until later in the treatment period. 
 
 To assess the contribution of Sit4 to these dynamic changes in Hst4 protein levels, 
we engineered sit4Δ and tco89Δ sit4Δ into the Hst4-9xMyc background and again 
examined Hst4 expression. Excitingly, we found that deletion of SIT4 in the wild-type 
Hst4-tagged strain significantly reduced Hst4 levels, and the combinatorial mutant, 
tco89Δ sit4Δ, brought the elevated Hst4 levels observed in the tco89Δ single mutant back 
to approximately wild-type levels (Figure 3-11C, upper panel). We saw a much more 
muted response when the experiment was repeated with a series of sap4Δ mutants, a 
result consistent with the idea that there is functional redundancy among the Saps 
(Figure 3-11C, lower panel). Given TORC1’s known role in regulating transcription, we 
used qPCR and confirmed that the increase in Hst4 protein levels was not due to elevated 
HST4 mRNA expression (Figure 3-12). Therefore, these data suggest that the Sit4-
dependent effect on Hst4 expression is either translational or post-translational in nature.  
 
 Hst3 exhibits rapid proteasomal turnover, in a cell-cycle dependent fashion, in 
response to Cdk1 phosphorylation and subsequent SCFCdc4 ubiquitination [179, 180]. The 
phosphatase that opposes Cdk1-dependent Hst3 turnover is currently unknown. Hst4 was 
also identified as a potential SCFCdc4 substrate, but its proteolytic turnover has not been 
studied in nearly as much detail. We next asked whether the Sit4-dependent increase in 
Hst4 protein levels could be explained by a reduction in Hst4 turnover. To assess this 
possibility, we utilized our wild-type and tco89Δ strains expressing Hst4-9xMyc, and we 
examined the kinetics of Hst4 turnover in each. Cells were grown to log phase and then 
treated with cycloheximide (CHX), an inhibitor of protein synthesis. Excitingly, we 
found that relative to wild-type cells, the tco89Δ promoted a significant increase in Hst4 
stability (Figure 3-13A). We demonstrate this stabilization is Sit4-dependent, as the 
tco89Δ sit4Δ Hst4-9xMyc strain displays a turnover rate very similar to that of the wild-
type. We conducted the same experiment with WT and tco89Δ strains possessing an 
Hst3-9xMyc epitope for comparison, and surprisingly, found that in addition to the  
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Figure 3-11. Reduced TORC1 signaling activates PP6 to increase Hst4 protein 
levels. 
A. No tag, and WT or tco89Δ cells expressing indicated epitope-tagged sirtuins, were 
grown to log phase and analyzed by IB with Myc or G6PDH antibodies. B. No tag, WT 
Hst4-9xMyc, and tco89Δ Hst4-9xMyc cells were grown to log phase before treatment 
with MSX or rapamycin as indicated. WCEs were blotted for Myc and G6PDH and 
analyzed by ImageJ. Quantification of Hst4 levels relative to G6PDH are provided with 
the WT mock set to 1. C. No tag, WT Hst4-9xMyc, sit4Δ Hst4-9xMyc, sap4Δ Hst4-
9xMyc, tco89Δ Hst4-9xMyc, tco89Δ sit4Δ Hst4-9xMyc, and tco89Δ sap4Δ Hst4-9xMyc 
cells were grown to log phase and analyzed as in (B). Blots and expression values are 
representative of at least 3 independent biological replicates.   
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Figure 3-12. PP6-dependent changes in Hst4 protein levels are not due to increased 
HST4 mRNA expression. 
Hst3, Hst4 and Sir2 mRNA expression in wild-type, tco89Δ, hst4Δ, and tco89Δ hst4Δ 
cells. Means and SDs are presented and the data is representative of five independent 
experiments. Significance was determined by pairwise Student’s T-test. **-p<0.01; ***-
p<0.001.   
 43 
 
 
Figure 3-13. PP6 activation downstream of TORC1 inhibition initiates a reciprocal 
shift in Hst3/Hst4 stability. 
A. No tag, WT Hst4-9xMyc, tco89Δ Hst4-9xMyc and tco89Δ sit4Δ Hst4-9xMyc cells 
were grown to log phase and treated with 50 μg/mL cyclohexamide (CHX). Samples 
were taken just before CHX addition and then at subsequent intervals. Two exposures of 
the α-Myc blot are provided for clarity, and data quantification is shown on the right. 
Values are the mean and SD of four independent biological replicates, and significance 
was determined by pairwise Student’s t-test. *-p<0.05. B. As in (A) except Hst3 stability 
is measured. Time points differ as indicated.   
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increase in Hst4 stability in the tco89Δ mutant, there is also a reciprocal decrease in Hst3 
stability (Figure 3-13B). It is currently unclear whether this decrease is in direct response 
to the enhanced level of Hst4, or it is because Hst3 is a biologically relevant substrate of 
Sit4.  
 
 We next asked whether the Sit4-dependent change in Hst4 stability could be 
traced to direct opposition of sirtuin phosphorylation. To probe this possibility, we 
immunoprecipitated Myc-tagged Hst3 or Hst4 from WT and tco89Δ extracts and resolved 
them on Phos-tag containing SDS-PAGE gels. Phos-tag is a reagent that binds 
phosphorylated residues and reduces their electrophoretic mobility, allowing for more 
distinct resolution of phosphorylated compared to non-phosphorylated forms of a given 
protein. We observed a marked reduction in the slower migrating forms (phosphorylated) 
of both Hst3 and Hst4 in wild-type extracts treated with lambda phosphatase; however, 
no discernible difference was detected in the phosphorylation pattern of either sirtuin 
when wild-type and tco89Δ extracts were compared (Figure 3-14A). As a control, we 
repeated the experiment shown in Figure 3-14A using the downstream TORC1 
phosphotarget Sch9 (Figure 3-14B). We found a dramatic downward shift in Sch9 
mobility in both the lambda phosphatase treated sample, as well as the rapamycin treated 
sample, confirming that the Phos-tag reagent behaves as expected. In all, these findings 
identify a novel mechanism in which TORC1 inhibition promotes Sit4 activation and 
site-specific histone deacetylation via stabilization of Hst4. These effects appear to occur 
independently of a direct role for TORC1 in Hst4 phosphorylation status.  
 
 
Hst4 Nuclear Accumulation Occurs Rapidly as a Consequence of TORC1 Inhibition 
and Sit4 Activation, and Precedes the Increase in Hst4 Stability  
 
 It was previously reported that metazoan SIRT1 and SIRT2, as well as yeast Hst2 
and Hst4, actively shuttle between subcellular compartments in response to starvation, 
cellular stress or cell-cycle progression (summarized in Tables 1-1 and 1-2) [168, 176, 
188, 222, 312]. As outlined in Chapter 1, the best-known function of Sit4 activation 
downstream of TORC1 inhibition involves regulation of transcription factor localization 
to coordinate the NCR response. We therefore considered whether Sit4/PP6 activity 
might stabilize Hst4 by altering its subcellular distribution. Utilizing the wild-type and 
tco89Δ sirtuin 9xMyc-tagged strains described above, indirect immunofluorescence 
(Figures 3-15 and B-3) and quantitative analysis (Figure 3-16A) was performed as 
detailed in Chapter 2. Of the five sirtuins, Hst4 exhibited the most significant alteration in 
cellular localization, as diffuse staining throughout wild-type cells was considerably more 
nuclear focused in tco89Δ (Figures 3-15, 3-16A, B-3D). 
  
 To determine whether the increase in Hst4 protein levels occurred before or after 
the nuclear accumulation of Hst4, we repeated the experiment described in Figure 
3-16A, this time including an additional wild-type sample treated with 200 nM 
rapamycin for 20 minutes. Importantly, we saw that the 20-minute rapamycin treatment, 
which previously had very little effect on protein levels (Figure 3-11B), was sufficient to 
promote maximal nuclear accumulation of Hst4 (Figures 3-16B and B-3D). This  
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Figure 3-14. Hst3 and Hst4 phosphorylation state is independent of TORC1 
function. 
A. Wild-type (WT) Hst3-9xMyc, tco89Δ Hst3-9xMyc, WT Hst4-9xMyc and tco89Δ 
Hst4-9xMyc were grown to log phase and extracts were prepared. Hst3 and Hst4 were 
immunoprecipitated from 1 mg of extract, and the sirtuin bound IgG-conjugated beads 
then were treated with lambda phosphatase for 1 hour at 30°C as indicated. IP samples 
were resolved on 10% SDS PAGE gels containing Phos-tag (50 μM) and evaluated by α-
Myc IB. Input gels were run in parallel where 35 μg extract was resolved on 10% SDS 
PAGE gel without Phos-tag present. B. As in (A), except Sch9-6xHA strains were 
utilized.  
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Figure 3-15. TORC1 suppression drives Hst4 nuclear accumulation in a Sit4-
dependent fashion. 
Wild-type, tco89Δ, and tco89Δ sit4Δ strains containing either no tag or a 9XMyc epitope 
on Hst4 were grown to log-phase, fixed, permeabilized, and imaged using indirect 
immunofluorescence as described in Chapter 2. Images are representative of at least five 
biological replicates. DAPI staining denotes the nucleus and the α-Myc (FITC) tracks the 
localization of Hst4.  
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Figure 3-16. Hst4 nuclear accumulation occurs rapidly as a consequence of 
TORC1 inhibition and precedes the increase in Hst4 protein stability. 
A. Nuclear ratios of the sirtuins were determined from a series of images, as described in 
Chapter 2, and graphed. Means and SDs presented are representative of five or more 
biological replicates. Each replicate contained 20-40 randomly selected cells. B. Wild-
type Hst4-9xMyc cells were grown to log phase and mock or rapamycin treated (300 nM 
rap, 20 min) before analysis as described in (A). tco89Δ Hst4-9xMyc and tco89Δ sit4Δ 
Hst4-9xMyc strains were included for comparison. Significance was determined by 
pairwise Student’s t-test. *-p<0.05; **-p<0.01.  
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correlated well with the timing of the acetylation response (Figure 3-1C). Finally, in a 
tco89Δ sit4Δ Hst4-9xMyc strain, which displays a wild-type level of Hst4 expression and 
turnover (Figures 3-11C and 3-13A), the cellular distribution of Hst4 was corrected 
(Figures 3-15 and 3-16B). Therefore, Sit4 activation is required to promote Hst4 nuclear 
localization and rapid histone deacetylation (within 20 minutes), and the subsequent 
stabilization of this nuclear HDAC (60 minutes post-TORC1 inhibition) likely sustains 
the hypoacetylation phenotype until TORC1 activity is restored. 
 
 
TORC1-Dependent Histone Acetylation Does Not Impact RP Gene Transcription, 
But Does Contribute to a Subset of TORC1-Regulated Biological Functions  
 
 TORC1 had been previously identified as a regulator of acetylation at the rDNA 
and the RP genes, and our lab recently characterized a critical role for TORC1-mediated 
H3K56ac in RNA polymerase I-dependent rDNA transcription [12, 13, 66, 140, 142]. 
Given this, and TORC1’s well-established link to anabolism, we next asked whether 
these TORC1-regulated acetylation states contributed to the transcriptional regulation of 
ribosome biogenesis. In the initial characterization of Tco89, it was reported that tco89Δ 
mutants had no effect on ribosomal protein gene expression [43]. However, we chose to 
revisit these claims as the authors did not present the data or identify the genes they had 
assayed. Utilizing cDNA from Figure 3-12, we examined how decreased acetylation 
(WT to tco89Δ), and subsequent restoration (tco89Δ to tco89Δ hst4Δ), impacted 
expression of a subset of RP genes encoding both small and large ribosomal subunits. We 
found that in the tco89Δ mutant, where TORC1 function is decreased (Figure B-1) and 
we observe a global site-specific reduction in acetylation (Figure 3-1A), there is not a 
significant effect on RP mRNA levels (Figure 3-17). The hst4Δ had a similarly 
negligible effect, while tco89Δ hst4Δ resulted in a moderate yet significant reduction in 
RPL23B expression (Figure 3-17).  
 
 tco89Δ mutants have been reported to enter an irreversible, growth-arrested state 
following TORC1 inhibition [49]. A number of characterized physiological states and 
compounds can promote this permanent growth-arrest, including nutrient starvation, 
rapamycin, the DNA damaging agent hydroxyurea, and the metalloid arsenic trioxide [57, 
313]. And while the ultimate cellular response is often similar, the mechanisms 
underlying these effects can be very diverse [314]. We next determined if restoration of 
TORC1-regulated acetylation could rescue the sensitivity of tco89Δ mutants to these 
TORC1 inhibitors. Excitingly, we found that pairing an hst3Δ or hst4Δ with tco89Δ 
reversed its sensitivity to low dose rapamycin (5 nM), as well as to hydroxyurea and 
arsenic trioxide (Figure 3-18). These spotting data were surprisingly distinct from what 
was observed with the tco89Δ sit4Δ across the same spectrum of conditions. Although 
tco89Δ sit4Δ was sufficient to restore wild-type growth on hydroxyurea and arsenic, it 
failed to enable growth on rapamycin (Figure 3-18).  
 
 A previous study suggested that Hst4 may be the functional ortholog of the 
metazoan mitochondrial SIRT3 [176]. This study demonstrated that Hst4 localization to 
the mitochondria fluctuates in response to vitamin availability (biotin), and that this effect  
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Figure 3-17. Global loss of TORC1-responsive acetylation marks does not correlate 
with a change in expression of a subset of ribosomal protein genes. 
WT, tco89Δ, hst4Δ and tco89Δ hst4Δ cells were grown to log phase, cDNA was 
synthesized from total RNA, and qPCR was performed with the primer sets indicated.  
Data are the average and SD of four independent experiments and significance was 
determined by pairwise Student’s t-test. **-p<0.01.  
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Figure 3-18. TORC1-PP6 regulated histone acetylation is functionally significant 
for a subset of TORC1-dependent processes. 
WT, tco89Δ, hst3Δ, tco89Δ hst3Δ, hst4Δ, tco89Δ hst4Δ, sit4Δ and tco89Δ sit4Δ were 
cultured to saturation overnight. Cells were five-fold serially diluted and spotted onto the 
indicated plate media. Images were obtained after four days at 30°C.   
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correlates with changes in mitochondrial protein acetylation, cellular respiration, and 
reactive oxygen production. Given the similarities between the biotin signaling 
mechanism, and the one we described above, we asked whether the nitrogen responsive 
TORC1-PP6-sirtuin cascade may also impact mitochondrial function. To explore this 
concept, wild-type, tco89Δ, hst4Δ and tco89Δ hst4Δ cells were either mock treated or 
treated with a low concentration (5 nM) of rapamycin for 2 hours. Cells were then stained 
with DHE to detect reactive oxygen species (ROS). TORC1 inhibition, via rapamycin 
treatment or tco89Δ, had relatively little effect on ROS production relative to wild-type 
mock-treated cells (Figure 3-19). In agreement with the biotin study [176], deletion of 
HST4 did indeed trigger a decrease in basal ROS levels in both the wild-type and the 
tco89Δ backgrounds (Figure 3-19). Considering TORC1 inhibition did not have an effect 
on ROS production, it would seem that the link between Hst4 and ROS occurs 
independently of our newly-characterized PP6-dependent mechanism. Still, this is an 
interesting development and provides insight into another biologically relevant function 
for this sirtuin.  
 
 In all, our data illustrate the existence of a novel TORC1-PP6-sirtuin signaling 
cascade that coordinates the epigenetic modification of histones with changes in 
environmental nitrogen availability. Further, we demonstrate that the downstream 
activation of sirtuins, in response to TORC1 inhibition, plays a critical role in an array of 
cellular operations, including cell cycle re-initiation following stress and DNA repair. 
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Figure 3-19. Hst4 contributes to cellular ROS levels independently of TORC1. 
WT, hst4Δ, tco89Δ and tco89Δ hst4Δ cells were cultured to log phase and mock or rap 
treated (5 nM) for 2 hours. Cells were then washed and stained with DHE for 20 minutes 
prior to analysis by flow cytometry. Data presented are the average and standard 
deviations of five independent experiments. Significance was determined by pairwise 
Student’s t-test. *-p<0.05; **-p<0.01. 
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CHAPTER 4.    HMG DISPLACEMENT OCCURS INDEPENDENTLY OF 
TORC1-MEDIATED HISTONE ACETYLATION TO PROMOTE A NOVEL, 
STRESS-RESPONSIVE CELL DEATH  
 
 
H3K37A Mutation Correlates with HMGB Nuclear Delocalization and Is Sufficient 
to Change Rapamycin from a Cytostatic to a Cytotoxic Agent  
 
 Our lab previously identified a significant and unique genetic link between 
TORC1 signaling and one particular histone tail residue, H3K37 [152]. Using a library of 
histone mutants in which each residue has been individually mutated to alanine [315], we 
screened for altered sensitivity to the TORC1 inhibitor rapamycin. H3K37A turned out to 
be the only mutant in the library that, when treated with low doses of rapamycin, 
exhibited a dramatic loss of viability ([152] and Figure 4-1A). This rapamycin sensitivity 
proved to be independent of histone post-translational modification however, as replacing 
the native lysine with an amino acid that mimics acetylation (glutamine), or simply 
restores its charge (arginine), rescued the rapamycin phenotype (Figure 4-1A, lower 
panel). The only known function for H3K37 in the cell is to anchor HMGBs to chromatin 
[252, 253, 316, 317]. In previous work from our laboratory, we hypothesized that the cell 
death caused by TORC1 inhibition in H3K37A cells was attributable to nuclear 
delocalization of HMGBs [152]. Given the findings presented in Chapter 3, we sought to 
expand on this previous work to probe whether TORC1-regulated histone acetylation 
may contribute to the binding of HMGBs to chromatin. 
 
 Initially, we screened for other HMGB proteins that may behave similarly to the 
previously characterized Nhp10 [152]. We found that Nhp6a is also displaced from the 
nucleus in H3K37A cells following transient low dose exposure to rapamycin (Figure 
4-1B). Nhp6a delocalization does not occur in an H3K37R mutant (Figure 4-1B), which 
fits with the fact that H3K37R cells are not sensitive to TORC1 inhibition (Figure 4-1A). 
Together, this shows that there is a strong correlation between HMGB delocalization and 
the overall health of the cells under TORC1-limiting conditions. Critically, while HMGB 
release into the cytoplasm occurred 60 minutes post-rapamycin treatment (Figure 4-1B), 
a significant increase in cell death was not observed until between 60 and 90 minutes 
post-rapamycin (Figure 4-1C). These data support our hypothesis that HMGB nuclear 
delocalization may drive induction of apoptosis/necrosis under TORC1-limiting 
conditions, rather than simply occurring as a consequence of cell death. We next asked 
whether H3K37A mutants would be less sensitive to rapamycin if Hst4 (the sirtuin 
opposing TORC1-dependent histone acetylation) or Sap4 (one of the ancillary PP6 
subunits critical for stabilizing Hst4 under TORC1-repressive conditions) were deleted. 
hst4Δ had no effect on Nhp6a localization (Figure 4-2A), nor did hst4Δ or sap4Δ restore 
cellular viability following rapamycin treatment (Figure 4-2B). Additionally, there was 
no significant growth advantage for the H3K37A hst4Δ or the H3K37A sap4Δ during 
transient or long-term rapamycin exposure (Figure B-4A and B-4B respectively). And 
finally, H3K37A mutants plated on media containing both nicotinamide and rapamycin 
did not show improved growth compared to rapamycin alone (Figure B-4C).   
 54 
 
 
Figure 4-1. The H3K37A mutation correlates with HMGB nuclear delocalization 
and converts rapamycin from a cytostatic to cytotoxic agent. 
A. Strains from a previously described histone mutant library [315] were grown to 
saturation, five-fold serially diluted, and spotted onto YPD control plates or YPD + 20 
nM rapamycin. A cartoon illustrating relevant H3 N-terminal tail residues is provided, 
and H3K37 is highlighted in pink. See text for more details. B. H3WT and H3K37A cells 
expressing Nhp6a-EGFP were either mock or 20 nM rapamycin treated for one hour. 
Confocal microscopy images were obtained and analyzed as described in Chapter 2. 
Quantification of this data is provided, with means and SDs plotted. Significance was 
determined by pairwise Student’s t-test. **-p<0.01. C. H3WT and H3K37A were 
cultured to log phase and then mock or 20 nM rapamycin treated for increasing lengths of 
time as denoted below. Cells were stained with YO-PRO-1 and PI and analyzed by flow 
cytometry. Averages and SDs are representative of three independent experiments. Data 
source: personal communication with Dr. Hongfeng Chen, May 2016.   
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Figure 4-2. Partial restoration of TORC1 responsive histone H3/H4 acetylation 
does not reverse Nhp6A nuclear delocalization or cell death. 
A. H3WT and H3K37A expressing Nhp6a-EGFP, and the matched hst4Δ mutants, were 
either mock or 20 nM rapamycin treated for one hour. Confocal microscopy images were 
taken and analyzed as described in Chapter 2. Averages and standard deviations are 
presented, and are representative of at least 3 independent biological replicates. 
Significance was determined by pairwise Student’s t-test. *-p<0.05. B. H3K37A, 
H3K37A hst4Δ and H3K37A sap4Δ were cultured to log phase and then mock or 20 nM 
rapamycin treated for one hour prior to staining with YO-PRO-1 and PI and FACS 
analysis. The data are the average and SD of three independent experiments. Matched 
H3WT samples were analyzed in parallel (including sap4Δ and hst4Δ strains), however 
there was not any detectible apoptosis or necrosis in those samples. Data source for 
Figure 4-2A: personal communication with Dr. Hongfeng Chen, May 2016.   
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 Overall, while these data do support a functional role for H3K37 as a vital contact 
residue for HMGB-chromatin binding under conditions of TORC1 inhibition, they argue 
against the hypothesis that TORC1-dependent acetylation contributes to this association. 
An alternative possibility could be that the TORC1-dependent chromatin changes 
detailed in Chapter 3 may function in parallel with H3K37 to suppress cell death. It is 
important to emphasize that we have demonstrated there is some functional redundancy 
amongst the sirtuins and Saps in their effects on histone acetylation. Therefore, in the 
absence of Hst4 or Sap4, additional Saps or sirtuins may partially compensate and thus, 
mask their potential contributions to this process. We chose to use these strains as we 
were unable to create an H3K37A sit4Δ mutant, which presumably would have had a 
greater effect on acetylation, and possibly rapamycin sensitivity.  
 
 
Aberrant HMGB Expression and Localization Result in Vacuolar Acidification and 
Apoptotic and Necrotic Cell Death through a Novel Death Pathway 
 
 We next investigated the cell death mechanism triggered by HMGB displacement 
in H3K37A mutants following TORC1 inhibition. Previously, we noticed that the 
H3K37A cells displayed abnormal vacuolar morphology even prior to TORC1 
suppression [152]. It was unclear at the time whether these vacuoles were dysfunctional, 
or if this was simply a sign of a compensatory increase in autophagy. We speculated that 
these changes in vacuole morphology may be linked to the cell death phenotype observed 
in TORC1-suppressed H3K37A cells. To explore this concept, H3 wild-type (H3WT) 
and H3K37A mutants were stained with CFDA, a dye which is used to visualize changes 
in vacuolar pH. Confocal microscopy analysis identified significant vacuole acidification 
in H3K37A mutants following 60 minute rapamycin exposure, whereas no change in pH 
was detected in similarly treated H3WT cells (Figure 4-3A). Importantly, the timing of 
acidification correlates with the nuclear release of HMGBs, which again, occurs prior to 
significant cell death (Figure 4-1C). Vacuole acidity was quantified by flow cytometry 
and steadily increased for hours in the rapamycin-treated H3K37A mutant (Figure 4-3B). 
There was no discernible change in the rapamycin-treated H3WT cells over this same 
period. Together, these results would suggest that cytoplasmic HMGBs may be 
promoting cell death, in part, via vacuolar dysfunction.  
 
 To demonstrate this vacuolar acidification is directly attributable to HMGB 
delocalization, we next asked whether aberrant HMGB expression caused a similar 
constellation of vacuolar effects in an otherwise wild-type cell. To accomplish this, we 
transformed H3WT cells with galactose-inducible Nhp6a or Hmo1 expression vectors. 
Cells were cultured in raffinose, treated with 2% galactose for 20 minutes, and then 
stained with CFDA and quantified by flow cytometry analysis. Unfortunately because 
vacuolar pH is highly responsive to metabolic changes, even transient galactose induction 
in minimal raffinose media led to increased acidity in the control cells, thus confounding 
data analysis (data not shown). Still, because the galactose-inducible promoter is leaky, 
confirmed by immunostaining for HMGB expression in the absence of galactose (Figure 
B-5), we attempted the experiment in minimal raffinose media without galactose 
induction. Excitingly, we were able to recapitulate the decrease in vacuolar pH by simply  
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Figure 4-3. Aberrant HMGB localization results in vacuolar acidification. 
A. H3WT and H3K37A cells were grown to log phase in YPD and then mock or 20 nM 
rapamycin treated for 20 minutes. Cells were stained with CFDA and imaged via direct 
confocal microscopy as described in Chapter 2. Arrows denote cells with increased 
vacuolar acidity. B. As in (A), except rapamycin treatment was extended to 1-3 hours and 
analysis was conducted by flow cytometry. C. H3WT cells transformed with control 
vector or galactose-inducible NHP6A or HMO1 vectors were grown to log phase in YP-
Raffinose. Cells were then stained with CFDA and analyzed by flow cytometry. D. 
Quantification of the average and SD of the peak CFDA fluorescence of the entire gated 
population shown in (C). E. Quantification of the average cell number and SD of the 
bracketed population in (C). Data are representative of five independent experiments. 
Significance was determined by pairwise Student’s T-test. **-p<0.01; ***-p<0.001. Data 
source for Figure 4-3A: personal communication with Dr. Hongfeng Chen, May 2016.  
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deregulating HMGB expression/subcellular distribution in an otherwise wild-type cell 
(Figure 4-3C, D and E). We identified a shift in total CFDA signal (Figure 4-3C, 
quantified in 4-3D), indicative of a decrease in the average vacuolar pH. Additionally, we 
observed a change in the overall population distribution toward a more acidic pH 
(denoted by bracketed population in Figure 4-3C, quantified in Figure 4-3E).  
 
 Our time course experiments suggested that vacuole acidification occurred prior 
to any significant loss of viability (Figure 4-3B). However, it remained unclear whether 
the cell death downstream of TORC1-dependent HMGB displacement was directly 
caused by the decrease in vacuolar pH. To address this point, we incorporated MES into 
our plate media to ask whether pH buffering could rescue the H3K37A rapamycin 
phenotype. We found that the H3K37A cells were significantly less sensitive to 
rapamycin when cellular pH was buffered (Figure 4-4). These results further support our 
hypothesis that TORC1 inhibition in H3K37A, and the resulting HMGB delocalization, is 
an initiator of cell death through aberrant vacuolar acidification. 
 
 
H3K37A Mutants Display Increased TORC1 Activity, Which Correlates with 
Displacement of HMGBs and Can Be Reversed by HMGB Deletion 
 
 Our findings to this point illustrate a strong correlation between HMGB 
delocalization and vacuolar dysfunction. We previously hypothesized that one reason the 
H3K37A mutant is hypersensitive to rapamycin is that, while H3K37 serves as the main 
chromatin docking site for HMGBs, TORC1-dependent histone acetylation states may 
contribute to HMGB chromatin binding as well. However, the data presented in Figure 
4-2 would suggest instead that TORC1 signaling and HMGB binding may function in 
parallel to synergistically regulate cell survival. In the process of performing the 
experiments with the H3K37A hst4Δ and H3K37A sap4Δ strains (Figure 4-2), we 
serendipitously discovered that H3K37A mutants have a dramatic increase in basal 
TORC1 activity as demonstrated by S6 phosphorylation (Figure 4-5A).  
 
 Recently an insightful review was published by Eltschinger and Loewith [318] 
describing a series of feedback loops centered around TORC1. Given that TORC1 
complex activation is tightly linked to vacuolar processes, we speculated that the nuclear 
displacement of these HMGs downstream of TORC1 might alter vacuole function to 
feedback and affect complex activity. Strikingly, wild-type cells transformed with 
galactose-inducible HMG plasmids exhibited significantly elevated TORC1 signaling 
relative to control vector expressing cells (Figure 4-5B). Additionally, we found that 
genomic deletion of the HMGs previously identified as having TORC1-responsive 
cytoplasmic localization (Nhp6a and Nhp10) was sufficient to reduce TORC1 signaling 
in both H3WT and H3K37A backgrounds (Figure 4-5C). This effect is specific as 
deletion of HMO1, a gene encoding an HMG whose nuclear localization was unaffected 
by both H3K37A and TORC1 inhibition [152], had no effect on TORC1 function (Figure 
4-5C). Altogether, these findings confirm that delocalization of HMGs in both H3WT 
and H3K37A backgrounds, particularly the nuclear to cytoplasmic translocation of  
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Figure 4-4. Buffering intracellular pH is sufficient to partially reverse the 
rapamycin sensitivity of an H3K37A mutant. 
H3WT and H3K37A cells were grown to log phase, five-fold serially diluted, and spotted 
to indicated media conditions. Data source: personal communication with Dr. Hongfeng 
Chen, May 2016.   
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Figure 4-5. H3K37A mutants display increased TORC1 activity that depends on 
the presence of specific HMGB factors. 
A. H3WT and H3K37A cells were grown to log phase and mock or rapamycin treated 
(20 nM) for 60 minutes. Extracts were prepared and analyzed by IB as indicated. B. 
H3WT cells transformed with galactose-inducible, HA-tagged, HMGB expression 
vectors were grown to log phase in raffinose media prior to 2% galactose induction for 20 
minutes. Samples were processed and analyzed as in (A). C. H3WT and H3K37A strains 
were constructed in which the indicated individual HMGB genes were deleted. Strains 
were grown up to log phase in YPD and analyzed by IB as in (A).   
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Nhp6a and Nhp10, is sufficient to promote vacuolar dysfunction and an overall increase 
in TORC1 activity.  
 
 In all, the work presented in this chapter suggests that H3K37 does indeed serve 
as a docking site for high-mobility group proteins in vivo, though whether TORC1-
responsive acetylation states contribute to HMGB chromatin binding is questionable. 
Disruption of HMGB chromatin association results in apoptotic and necrotic cell death 
marked by aberrant vacuolar pH and elevated TORC1 function.  
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CHAPTER 5.    INVESTIGATING THE ROLE OF TCO89 IN TORC1 
 
 
Identification of the Domain Necessary for Tco89-Dependent TORC1 Functions  
 
 Very little is known about the function of the S. cerevisiae TORC1 subunit 
Tco89, and structurally, we know virtually nothing. As was mentioned in Chapter 1, 
homologs have been identified in S. pombe and C. albicans, though curiously, it is 
currently the only yeast TORC1 subunit without an obvious mammalian ortholog [52, 
53]. There is evidence that Tco89 bridges TORC1 and the vacuole [49], coordinates 
vacuolar function via Vac8 [62], and also regulates site-specific histone acetylation [66]. 
Previous studies summarized on the Saccharomyces Genome Database demonstrate that 
tco89Δ cells have abnormal cellular physiology and budding patterns, as well as 
dramatically increased sensitivity to heat, caffeine, MMS, rapamycin and salt [52, 54-60]. 
Allowing tco89Δ cells to reach stationary phase where nutrients are limiting, or treating 
them with rapamycin, results in an irreversible cell-cycle arrest [49, 61]. These effects 
demonstrate that loss of this subunit enhances cellular sensitivity to TORC1 inhibition. 
Interestingly, these mutants are also described as having a decreased rate of carbon and 
nitrogen metabolism [319]. We believe a better understanding of Tco89’s role within the 
complex could provide insight into whether a similar subunit exists within mammals. If 
so, targeting such a factor pharmacologically could greatly enhance the clinical efficacy 
of mTORC1 inhibitors.  
 
 We first wanted to identify the key domains of the protein required for its 
function. We constructed a series of N-terminal Tco89 truncation mutants, each 
displaying a C-terminal FLAG epitope tag. Very little is currently known about the 
structure of Tco89, so we utilized the PSI-PRED prediction profiling software as a guide 
for where to draw our boundaries between clones (Figure 5-1A) [302]. It was our hope 
that with this information we could avoid truncating in the middle of a domain, which 
would likely confound our analysis. Our cloning strategy is shown in full in Figure 5-1A. 
We demonstrated that all of our truncations are stable and expressed at approximately 
equal levels in Figure 5-1B. While the particular blot presented in Figure 5-1B appears 
to have less of clone B present, we note that this is not a consistent result. There seemed 
to be a degree of fluctuation across the independent transformations which is not 
currently understood, but we never observed a pattern that would suggest one clone is 
more or less stable than the rest, nor did these fluctuations ever seem to correlate to a 
difference in screened phenotypes.  
 
 Wild-type and tco89Δ cells transformed with control vector, a vector expressing 
full-length Tco89, or various Tco89 truncations, were grown overnight to saturation. 
Equivalent numbers of cells were then serially diluted and spotted onto control selection 
plates, and selection plates containing rapamycin or caffeine (Figure 5-2A). The 
phenotype of each mutant grown on these various TORC1 inhibitors was qualitatively 
scored using a previously described method [152]. These values were averaged and are 
shown in heat map format in Figure 5-2B. Clearly, there is a dramatic difference in 
rapamycin sensitivity comparing fragment C to fragment D, which would indicate that  
 63 
 
 
Figure 5-1. Construction of Tco89 mutant expression vectors. 
A. Diagram of cloning strategy used to create a series of N-terminal truncations of the 
TORC1 subunit Tco89. Constructs contain a C-terminal FLAG epitope for visualization. 
PSI/PRED prediction software was used to locate probable secondary structure, and the 
software profile information is provided [302]. Predicted α helices are denoted in red and 
β strands in blue. B. tco89Δ cells were transformed with control vector (CV), or vectors 
containing full-length Tco89 (FL) and the truncations (A-F). Transformants were grown 
to log phase under selection, and whole cell extracts were prepared and blotted for FLAG 
to confirm expression. Arrows denote the seven Tco89 truncation fragments. G6PDH is 
provided as a loading control.  
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Figure 5-2. Identification of the functional domain necessary for Tco89-
dependent TORC1 functions.   
A. WT cells transformed with control vector, and tco89Δ strains expressing the series of 
Tco89 truncation vectors, were grown to stationary phase, five-fold serially diluted and 
spotted to TORC1 inhibitory conditions as indicated. Images are representative of growth 
following four days incubation. Growth on various conditions was scored on a -3 to 3 
scale as described previously [305], and in Chapter 2. B. Quantification of growth 
phenotype scores from (A). Data is presented as a heat map, with red indicating 
decreased growth compared to wild-type, white indicating no change, and green 
representing an increase in viability. Scores are the average obtained from at least five 
independent transformations. C. Strains of interest from (A) were grown to log phase and 
extracts were prepared. Samples were analyzed by immunoblot as indicated.  
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amino acids 465-399 are critical for maintaining the cell’s ability to grow when TORC1 
activity is reduced. Interestingly, a similar effect is seen with caffeine between fragments 
B and C, suggesting that Tco89 may mediate the cellular response to rapamycin and 
caffeine in different ways. Although fascinating, this result is not entirely surprising 
given previous work that indicated rapamycin and caffeine affect TORC1 function 
disparately [320], and that caffeine may inhibit TORC1 in a Tco89-dependent fashion 
[62].  
 
 Finally, we explored whether the dramatic shift in spotting phenotypes observed 
between fragments C and D correlated with a decline in TORC1 activity. Cells from 
Figure 5-2A were grown to log phase, WCEs were prepared, and TORC1 signaling was 
assessed by blotting for phosphoS6. In Figure 5-2C, we demonstrated that indeed there is 
an almost complete loss of steady state TORC1 function from fragment C to fragment D, 
which correlates nicely with the significant increase in sensitivity to rapamycin and 
caffeine (Figure 5-2A and 5-2B). We had hoped to utilize these truncation mutants for 
further phenotypic evaluation, however given that our selectable marker was auxotrophic, 
and all of our processes of interest are highly responsive to nutrients, the necessity of 
growing cells on defined media to select for the plasmids led to confounding results (data 
not shown). 
 
 
The Observed Cell Cycle Arrest in tco89Δ Upon TORC1 Limitation Is Not 
Attributable to Dysregulation of Reactive Oxygen Production 
 
 We next wondered whether tco89Δ’s dramatic sensitivity to TORC1 inhibitors 
could be partially alleviated by removal of an upstream negative regulator of TORC1. To 
assess this possibility, we deleted the gene encoding NPR3, a Gtr1 GTPase that 
suppresses TORC1 signaling. We found that loss of this negative regulator was not 
sufficient to overcome the observed rapamycin sensitivity, as tco89Δ npr3Δ grew just as 
poorly as tco89Δ (Figure 5-3A). This likely means that Npr3 inhibition of TORC1 occurs 
upstream of tco89Δ. 
 
 Given the reported nutrient utilization phenotypes of a tco89Δ [319], and 
considering that TORC1’s effect on lifespan has been suggested to occur, in part, through 
mediation of mitochondrial ROS signaling [321-325], we next examined the effect loss of 
Tco89 has on mitochondrial function. Previous findings demonstrated that in wild-type 
cells, the transition from log phase to stationary phase is marked by a dramatic increase in 
ROS levels [321]. Interestingly, tor1Δ displays increased basal levels of ROS, though 
there is a negligible effect on cellular ROS as this mutant transitions from log phase to 
stationary phase [321]. Early exposure to ROS in the tor1Δ is suggested to “toughen up” 
the cells, a phenomena known as hormesis [326]. The combination of hormesis and the 
reduction in stationary phase ROS has been hypothesized as one of the ways tor1Δ, and 
TORC1 suppression in general, contributes to an increase in lifespan.  
 
 We knew that in tco89Δ, nutrient limitation, TORC1 inhibition, or simply 
growing cells to saturation (late log phase) resulted in a permanent exit from the cell  
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Figure 5-3. Loss of Tco89 results in adaptive ROS response similar to that 
observed in tor1Δ. 
A. Wild-type (WT), npr3Δ, tco89Δ and tco89Δ npr3Δ cells were grown to stationary 
phase, five-fold serially diluted, and spotted onto YPD and YPD + 10 nM rapamycin. 
Photos provided are representative of growth after 3 days. B. WT and tco89Δ cells were 
grown to early log phase (OD~0.4) and mid stationary phase (OD~15). At both points, 
aliquots of cells were stained with DHE for 20 minutes followed by flow cytometry 
analysis. C. WT, tco89Δ and their corresponding mitochondrial-deficient strains (denoted 
?o) were grown to log phase, mock treated or treated with 25 nM rapamycin for 5.5 
hours, washed, and spotted onto YPD.   
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cycle [43, 49]. This led us to wonder what the ROS profile in a tco89Δ would look like as 
the strain transitioned from log phase to stationary phase, and whether dysfunction in the 
regulation of ROS production could possibly explain these cell cycle defects. Unlike 
tor1Δ, the tco89Δ displayed no significant increase in log phase ROS, though it did have 
a significant reduction in stationary phase ROS when compared to the wild-type cells 
(Figure 5-3B). The nature of the difference between tor1Δ and tco89Δ is not readily 
apparent, though given that log phase and stationary phase tco89Δ cells have nearly 
identical ROS levels, we can say that the observed cell cycle exit is not due to an inability 
to coordinate these ROS pathways. 
 
 Finally, we wondered whether compromising the mitochondrial genome (denoted 
?o) would have an effect on the normal growth of tco89Δ, or its response to transient 
TORC1 inhibition. Wild-type, tco89Δ, and their corresponding ?o  mutants were grown to 
log phase, mock treated or treated with rapamycin for 5.5 hours, washed and spotted onto 
YPD. The mock treated ?o mutants do tend to grow slower than the paired controls. 
However there does not appear to be any TORC1-dependent difference, as the tco89Δ ?o 
mutant is equally as sensitive to transient rapamycin treatment as tco89Δ (Figure 5-3C).  
 
 In total, this chapter represents the first structural assessment of the role of the 
Tco89 subunit within the TORC1 complex. Through construction of a series of truncation 
mutants, we identify the specific domain that is critical to allow cells to grow in the 
presence of TORC1 inhibition, and demonstrate that this domain is also critical for steady 
state TORC1 function. We report that the irreversible cell cycle arrest observed in 
nutrient deprived tco89Δ cannot be explained solely through defects in ROS signaling as 
cells transition from log phase to stationary phase. We believe these findings and tools 
will inform future studies to wholly characterize Tco89, and to determine whether it has a 
functional mammalian counterpart.  
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CHAPTER 6.    DISCUSSION AND FUTURE DIRECTIONS 
 
 
 It is critical for eukaryotes, whether they are single-celled yeast or multicellular 
organisms, to rapidly adjust their growth and proliferative profiles in response to 
intracellular deficits or changes in their extracellular environment. Studies from a number 
of labs suggest a regulatory link exists between TORC1 and the epigenome, including 
work in which we characterized the TORC1-responsive acetylation of H3K56 [66]. 
Additionally, we know from prior studies that a correlation exists between TORC1 
activity, histone acetylation, and HMGB chromatin binding [152]. At the outset of this 
study, we speculated that TORC1 signaling likely regulates other histone modifications 
besides H3K56ac, as it was demonstrated to mediate pan-H4 acetylation at the ribosomal 
protein genes [12], and that these modifications may contribute to anchoring HMGBs to 
chromatin. 
 
 
TORC1 and Histone Acetylation 
 
 In Chapter 3, we significantly expanded our understanding of the upstream stimuli 
linking TORC1 to the control of histone acetylation, and we gained an appreciation of the 
breadth of TORC1-responsive histone modifications. Foundational studies in the field 
utilized pan-H3 and pan-H4 acetyl antibodies to identify gross acetylation loss in 
response to TORC1 inhibition [12, 13]. But here we characterized for the first time the 
TORC1-mediated acetylation of H3K18, H3K23 and H4K12 (Figure 3-1). The 
specificity we observed is quite interesting and suggests inhibition of TORC1 is not 
promoting a global decrease in histone acetylation, nor is it a massive non-specific effect 
due to loss of all transcription-coupled marks (H3K4me3 is intact).  
 
 One possible explanation could be that inhibition of TORC1 results in a shift in 
metabolic intermediate availability, including acetyl CoA and NAD+, which feed into the 
acetylation and deacetylation reactions respectively. However, we would expect that if 
this were the case, the effects would be more universally observed across a multitude of 
histone residues. Rather this hypoacetylation appears to be a specific, site-directed 
response to decreased TORC1 function, as low-level pharmacological inhibition for a 
short time (20 minutes) is sufficient to induce the effect. Considering the existing link 
between TORC1 and the post-translational modification of H2A in the DNA damage 
response [327], it would be fascinating to probe other acetylation states such as H2AK7, 
H2AK21, H2BK11, and H2BK16, to see whether TORC1-responsive acetylation exists 
on H2A or H2B as well. We believe it is likely that TORC1-dependent histone 
modifications extend beyond acetylation, possibly to acylation (sirtuin substrate), 
phosphorylation, methylation, sumolyation, neddylation and others. Incorporation of 
mass-spectrometry based histone proteomics would provide us a more complete 
understanding of the diversity of the histone post translational modifications downstream 
of TORC1.  
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 TORC1 occupies a critical point in a pair of nutrient sensing axes. Amino acids 
and carbon both feed into the TORC1 signaling pathway, and each appears to do so, in 
part, through adaptive intracellular pH mechanisms [49, 80, 328]. Prior to this work, 
TORC1-responsive acetylation has been investigated exclusively by using the direct 
pharmacological TORC1 inhibitor, rapamycin. And while we also utilize rapamycin for 
this purpose, we extend our analyses to include several additional means of suppressing 
TORC1 activity. These stimuli are likely more physiologically relevant and thus, we 
examined their influence on our chromatin modifications of interest.  
 
 We provide striking evidence that not all TORC1 inhibition is equivalent at the 
level of acetylation, finding that nitrogen metabolism disruption (MSX), but not carbon 
limitation, led to decreased acetylation of a model TORC1 residue (Figure 3-2). The data 
presented argues against the previous claims that crosstalk between carbon metabolism 
and TORC1 signaling is responsible for our observed epigenetic effects [328, 329]. 
Instead, they suggest an interesting regulatory bifurcation through which cells may tailor 
their epigenome based on the specific nutrient they are lacking. There is likely a degree 
of overlap between nitrogen and carbon metabolism, as inhibition of TORC1 did not 
result in total ablation of our modifications of interest. Still, these findings illustrate that 
nitrogen signaling plays a vital and distinct role in the dynamic regulation of key 
acetylation sites. Additionally, they imply that signaling between vacuolar components 
(v-ATPase, EGO complex) and TORC1 is vital for the relay of environmental energy 
states to chromatin-based processes. Indeed a previous genetic screen of the yeast 
deletion collection found that a number of vacuole mutants display acetylation 
phenotypes [330]. We speculate that functions previously attributed to TORC1-mediated 
histone acetylation, including rDNA stability and regulation of RP gene expression [12, 
13], are also nitrogen specific given that the need for ribosomes and anabolic flux is 
reduced under starvation conditions. However, because these studies only utilized 
rapamycin to inhibit TORC1, it is impossible to be sure without delving back into those 
questions using specific amino acid starvation or suppression of general nitrogen 
metabolism via MSX.  
 
 In Chapter 3 we also present findings demonstrating that TORC1-dependent 
histone acetylation is regulated by sirtuin histone deacetylases. This corroborates our 
previous observation that deletion of HST3 and HST4 in the tco89Δ background is 
sufficient to rescue H3K56ac [66]. The connection between TORC1 and the sirtuins 
makes sense considering how intimately each is tied to cellular energy states. TORC1 
activity is most robust during times of nutrient abundance when cell growth and 
proliferation would be appropriate and advantageous, while sirtuins are most active when 
energy availability is limited (low NADH concentration, elevated NAD+/NADH ratio) 
[291]. The reciprocal arrangement between TORC1 and the sirtuins reported in yeast 
appears to be evolutionarily conserved, as mTORC1 suppression in metazoans promotes 
transcription of the SIRT4 gene [184].  
 
 Within our sirtuin results (Figure 3-10), we reported several previously 
unidentified, candidate substrates for each of the enzymes: Hst1 (H4K12ac), Hst2 
(H3K18ac), Hst3 (H3K18ac, H4K12ac), Hst4 (H3K18ac, H3K23ac, H4K12ac) and Sir2 
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(H4K12ac). Looking over these acetyl sites, we recognized several that are downstream 
of sirtuins in higher order organisms as well, including H3K18ac (deacetylated by SIRT6 
and SIRT7) and H3K56ac (deacetylated by SIRT6). SIRT6 regulation of H3K18ac was 
only recently identified, and was shown to occur at pericentric heterochromatin [237]. 
Hyperacetylation of H3K18ac in the absence of SIRT6 (which will also increase 
H3K56ac) leads to transcriptional activation of the otherwise silent pericentric chromatin, 
and accumulation of centromeric transcripts causes mitotic defects, genomic instability 
and cellular senescence. This is fascinating considering our data linking the yeast sirtuin 
Hst4, a regulator of H3K18ac, and the ability of tco89Δ cells to re-engage the cell cycle 
(or evade arrest entirely) in response to TORC1 inhibition. Additionally, the SIRT7-
dependent regulation of H3K18ac has been reported to promote oncogenic transformation 
and maintain tumorigenicity by disabling transcription of tumor suppressor genes [240, 
331, 332]. Notably, it was previously reported that overexpression of SIRT1 could 
complement loss of Sir2 in yeast [177].  
 
 We believe future complementation studies using vector-based human sirtuins in 
yeast deletion mutants could flesh out whether the human sirtuins are also responsive to 
TORC1, while highlighting which enzymes are most functionally conserved between 
humans and yeast. This would also provide significant evidence of mechanistic 
conservation of our described mechanism. A shortcoming of this portion is that to this 
point, all of the data linking TORC1 and specific acetylation states has been genetic in 
nature. Considering all the different pieces of evidence we have obtained, we are 
extremely confident that this observed phenomena is biologically real. Still, our stance 
would be significantly strengthened if we were to use biotinylated recombinant histones 
in in vitro deacetylation assays (such as the Fluor de Lys™ assay from Enzo Life 
Sciences [159]) to confirm that the sirtuins do in fact target these residues.  
 
 
The PP6 Phosphatase Complex and the TORC1-Dependent “Acetylome” 
 
 Our data demonstrate that when ample nitrogen is available, TORC1 regulates 
sirtuin-dependent site-specific histone H3/H4 acetylation through the suppression of the 
Sit4/PP6 complex and subsequently, enhanced Hst4 protein levels. One of the most 
compelling parts of this work involves how PP6 activation triggers this increase in Hst4 
expression. We first investigated whether HST4 gene transcription is regulated through 
the Sit4-mediated NCR stress response by deleting the Sit4-responsive transcription 
factors Gln3 and Gat1. The rationale being that if Hst4 protein levels are tied to Gln3 
and/or Gat1 function, deletion of these NCR components should result in a decrease in 
Hst4 protein and an increase in histone acetylation. It was clear however, that this was 
not the case. Loss of these transcriptional regulators did not have a positive effect on 
acetylation. Likewise, deletion of the cytoplasmic anchor that mediates their cytoplasmic 
localization upon nutrient stress did not promote a decrease in acetylation. We also find 
that TORC1 inhibition does not result in any increase in HST4 mRNA expression, all 
together suggesting that the elevated Hst4 protein levels that occur in response to TORC1 
inhibition occurs independent of HST4 transcriptional regulation or changes to HST4 
mRNA stability. Instead, we report a mechanism in which Sit4 activation promotes a 
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rapid, cytoplasmic to nuclear redistribution of Hst4, resulting in protein stabilization and 
a site-specific decrease in histone acetylation. The most important take away is timing, as 
we demonstrate that maximal nuclear accumulation occurs within 20 minutes (Figure 3-
16). Presumably, it is this population of Hst4 that promotes the immediate deacetylation 
observed upon acute rapamycin treatment. The subsequent increase in protein levels does 
not occur until some 40 minutes later (Figure 3-11), and we believe this stabilization 
sustains the hypoacetylation phenotype until TORC1 activity is restored.  
 
 In situations where we find a TORC1-dependent increase in Hst4 levels, we also 
observe a corresponding decrease in Hst3, which could suggest a regulatory balance 
exists between the amount of Hst3 and Hst4 in the cell. This possibility has already been 
hinted at in a work which demonstrated that the replication origin deficiencies observed 
in an hst3Δ cell could be overcome by expressing Hst4 under the control of the Hst3 
promoter [333]. Still, it is currently unclear as to how Sit4-PP6 activation results in Hst4 
nuclear accumulation (denoted by question marks in Figure 6-1). Our Phos-tag results 
(Figure 3-15) would suggest that this stabilization is not directly attributable to Sit4-
mediated sirtuin phosphorylation. However, we have only addressed this hypothesis with 
the Phos-tag approach, as our attempts to incorporate pan-phosphorylation antibodies and 
phosphostains were unsuccessful (data not shown). As a consequence, given what is 
known about the turnover of Hst3, we cannot yet exclude the possibility that Sit4-
dependent dephosphorylation of Hst3 or Hst4 does indeed regulate their function. Still, 
this leaves us to wonder about alternative explanations. Such as whether the phosphatase 
may coordinate sirtuin nuclear localization through regulation of importin (Srp1) and 
exportin (Xpo1) factors; the yeast carrier proteins responsible for actively chaperoning 
cargo proteins in and out of the nucleus. There is precedent for this as Hst2 shuttling is 
known to be regulated by Xpo1 [164]. Further, the import capacity of a mammalian 
ortholog of Srp1, importin α1, has been shown to be responsive to phosphorylation and 
acetylation [334].  
 
 Interestingly, it would appear that the identity of the Sit4-associated protein may 
confer an additional layer of specificity to the acetylation response, as we find that loss of 
Sap4 or Sap185 leads to a reduction in H3K18ac rapamycin sensitivity (Figure 3-6). 
Previous work examining rapamycin and zymocin sensitivity in yeast also identified 
dramatic phenotypic differences attributed to Sap association [100], though it is unclear 
what exactly the Saps contribute to these processes. Given the partial rescue observed in 
the sap4Δ and the sap185Δ, we speculate that these regulatory subunits are functioning at 
least somewhat redundantly to bridge the interaction between the Sit4 phosphatase and its 
downstream targets. Considering the high degree of conservation across this pathway, 
and that mammalian sirtuins are known to actively shuttle from the nucleus to the 
cytoplasm, we propose that future studies include pilot experiments asking whether 
exogenous human Sit4 (PPP6C) could complement Hst4 stability and localization in a 
sit4Δ cell. A similar approach could be conducted using the human Sap orthologs 
(PPP6R1/2/3). If it appears these mechanisms are indeed conserved, we could attempt to 
replicate these findings by monitoring acetylation in human cells with RNAi knockdown 
of PPP6C, PPP6R1/2/3, or the sirtuins which have been shown to shuttle intracellularly 
(SIRT1/2/3).   
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Figure 6-1. Proposed mechanism.   
Summary of work presented in Chapter 3 as discussed in Chapter 6. Areas requiring 
further study are denoted by question marks. See text for more details.   
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 Finally, it seems likely that TORC1 regulation of sirtuin function could contribute 
to changes in acetylation of non-histone substrates as well. The mammalian sirtuins, and 
particularly SIRT1, have been shown to target chromatin-modifying enzymes (p300, 
MOF, Tip60), as well as proteins involved in autophagy (FOXO1, FOXO3, LC3, 
Atg5/7/8), the stress-response (NF-?B, c-Myc, HIF-1α), metabolism (LKB1, PGC-1α) 
and DNA repair (Ku70, PARP1). Can we build on this information to define a TORC1-
responsive acetylome to better understand how aberrant mTORC1 signaling promotes 
disease? Could some of mTORC1’s canonical functions (anabolism, autophagy, and 
ribosome biogenesis) be partially attributed to mTORC1-dependent sirtuin localization? 
In addition to the yeast orthologs of the proteins mentioned above, there are a few other 
yeast candidate factors we propose evaluating in future studies. 
 
 
Spt7 
 
 Previous studies identified a replicative lifespan increase in mutants of the Gcn5-
containing SAGA histone acetyltransferase complex [335]. This observed lifespan 
extension could implicate TORC1 in coordination of SAGA function, and the fact that 
this effect requires Sir2 suggests the possibility that TORC1-dependent sirtuin activity 
could feed into SAGA. The Pep4-dependent processing of the SAGA subunit, Spt7, 
determines whether SAGA exists as a holocomplex or a subcomplex (also known as 
SLIK/SALSA) lacking Spt8 [336]. Spt7 has been shown to possess a bromodomain 
whose chromatin binding is sensitive to histone acetylation [337], and Spt7 has itself 
been suggested to be acetylated [163]. 
 
 We speculate that TORC1 may participate in regulating SAGA chromatin binding 
through coordination of H3 acetylation (Chapter 3). However, it is also possible that 
TORC1 may affect Spt7 acetylation via sirtuin stabilization to influence Spt7 processing, 
and SAGA composition or localization. It would be fascinating to utilize the previously 
described multi-epitope Spt7 strains [338] to assess TORC1 contributions to these SAGA 
dynamics. Further, we could immunoprecipitate Spt7 under same conditions and 
immunoblot to determine if its acetylation state is dependent on TORC1 activity. Either 
of these proposed mechanisms (histone acetylation dependent, direct effects on SAGA 
via Spt7) would enable TORC1 suppression to promote initial histone deacetylation 
through nuclear accumulation of Hst4, and also to feed back onto SAGA to prevent the 
incorporation of new histone acetyl marks. Together, these effects maintain a 
transcriptionally repressive chromatin state until environmental conditions improve.  
 
 
Ifh1 
 
 Ifh1is a coactivator of ribosomal protein gene transcription, and it is found at the 
RP promoters when environmental nutrient availability is sufficient to sustain growth. It 
is an essential gene that, when partially inactivated, results in an extension of lifespan 
marked by increased sensitivity to rapamycin and DNA damage. Gcn5 acetylates Ifh1 in 
a TORC1-responsive fashion, which allows for a RP transcriptional burst following 
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refeeding. Importantly, these Gcn5-dependent modifications are opposed by a subset of 
sirtuins. Together, this suggests the possibility that sirtuin localization/stabilization may 
communicate changes in TORC1 activity to ribosome biogenesis via Ifh1 acetylation or 
SAGA function (see above). If TORC1 regulates Ifh1 acetylation through a Sit4-sirtuin 
pathway, we would expect that loss of the phosphatase would render Ifh1 marks 
irresponsive to rapamycin. Similarly, if the hypothesis is correct, Ifh1 acetylation should 
fluctuate with MSX or nicotinamide treatment as well. 
 
 
Mitochondrial proteins 
 
 Lastly, we propose examining the acetylation state of mitochondrial proteins in 
response to TORC1 activity. We presented evidence in Chapter 3 that localization of 
Hst4 shifts toward a more nuclear distribution upon inactivation of TORC1. At the time 
we did not attempt to categorize where in the cytoplasm the mobilized Hst4 was coming 
from. However, we were inspired by a recent work that demonstrated Hst4 can localize to 
the mitochondria in a dynamic fashion and deacetylate mitoproteins [176], drawing 
parallels between yeast Hst4 and mammalian SIRT3 (see Table 1-2).  
 
 We speculate that when TORC1 is inhibited, mitochondrial Hst4 localizes to the 
nucleus. This means that not only does amino acid starvation promote deacetylation of 
nuclear proteins, but it also may result in an indirect increase in acetylation of 
mitochondrial proteins as a consequence of a depletion of mitochondrial-localized 
sirtuins. This could have a significant consequence on cellular metabolism, oxidative 
stress and mitochondrial efficiency. The possibility of a multi-organellar signaling web 
connecting the vacuole, the mitochondria, and the nucleus is tantalizing. Incorporating 
MitoTracker (Life Technologies) into our Hst4-9xMyc confocal studies (Figure 3-15), or 
immunoprecipitating mitochondrial proteins and evaluating whether they display 
TORC1-responsive acetylation, are comparatively quick and easy ways to determine 
whether the proposed connection would be worth pursuing. The aforementioned biotin 
study from Madsen et al. does provide us with a few candidates to work with, as they 
characterized the dynamic acetylation states of specific mitoproteins in the absence of 
Hst2, Hst4, or Sir2 [176]. We were able to use this data to determine which proteins are 
most highly responsive to Hst4 activity, and then stratify further by which targets’ 
acetylation seems to be specific for Hst4 (since we know only Hst4 is significantly 
relocalizing). There were a few hits that were particularly interesting and could warrant 
further study.  
 
 Asparagine synthetase displayed the greatest increase in acetylation in response to 
hst4Δ (30 fold), which would make sense if the TORC1-regulation of sirtuins promotes 
amino acid biosynthesis to attempt to overcome starvation. Fumarate reductase was also 
an interesting find as it functions in the electron transport chain, meaning that affecting 
its acetylation could result in changes in ATP production from mitochondria. And finally, 
isocitrate dehydrogenase is a possible candidate as well, as its p-value was very high and 
it plays a critical role in the TCA cycle. TORC1-regulated acetylation of either fumarate 
reductase or isocitrate dehydrogenase would suggest a linkage between environmental 
nutrient status and cellular bioenergetics at the mitochondria anchored by TORC1. 
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TORC1-Dependent Histone Acetylation and Anabolic Gene Transcription 
 
 TORC1 signaling is known to promote transcription of an array of anabolic genes 
involved in cellular growth and proliferation. Inactivation of TORC1 during starvation 
leads to reduced expression of these genes. However, the extent to which TORC1-
responsive histone acetylation contributes to these transcriptional dynamics remains 
unclear. To date, the most well-defined links between TORC1 and anabolic gene 
transcription are Sch9-dependent, yet we know that the histone acetylation response 
occurs through the Tap42-associated phosphatases, specifically PP6. We wondered then 
whether deleting components of our signaling pathway would result in changes to RP 
gene expression.  
 
 Somewhat surprisingly, in a TORC1 mutant (tco89Δ) where we have identified 
global acetylation defects, mRNA levels of select ribosomal protein genes are unaffected. 
Chen et al. provide a possible explanation for this, as they report that TORC1 regulation 
of the RP genes occurs in parallel with PKA [339]. This type of dual input allows for 
proper coordination of ribosome biogenesis with both carbon and amino acid availability, 
but also suggests that in tco89Δ, the low-level TORC1 activity (Figure B-1) paired with 
functional PKA may be sufficient to maintain RP gene expression. In our previous work 
characterizing TORC1-dependent rDNA transcription, we utilized H3K56A mutants, 
which would theoretically ablate all H3K56 acetylation in the cell. Therefore, another 
possible explanation for the lack of effect on RP gene expression could be that the low 
level of basal TORC1 activity retained in tco89Δ may be able to sustain local acetylation, 
and as a consequence transcription, despite the overwhelming global changes. This 
hypothesis is supported by the fact that the cells show no obvious growth deficiency 
under steady state conditions. 
 
 It is important to remember that TORC1’s transcriptional regulation reaches 
beyond just RP genes, so it is possible that other genes will be responsive to the reduced 
histone acetylation described here. Future studies incorporating ChIP-seq technology 
(identify genes with TORC1-responsive acetylation) and RNA-seq (quantify changes in 
gene expression in response to TORC1 inhibition) will be the foundation for examining 
how these modifications influence the transcriptional process. These data sets can be 
overlaid to identify genes whose acetylation patterns are TORC1-dependent and correlate 
with gene expression. Single gene ChIP and RT-qPCR analysis would confirm these 
findings, while also determining where on the gene (promoter/body) these modifications 
are occurring. Altered histone lysine acetylation may contribute to gene expression 
generally, by loosening the DNA-nucleosome contacts and enabling chromatin 
decondensation. But acetylation changes may also alter the docking of chromatin 
modifying complexes containing bromodomains or YEATS-domains [340, 341]. Gaining 
a greater understanding of how the chromatin association of these ancillary factors 
changes in response to TORC1 activity will be critical to defining how environmental 
nutrient availability influence anabolism at the level of transcription. Altogether, this 
information would provide significant insight into how these TORC1-responsive histone 
acetylation states affect chromatin-based processes.   
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Interplay between Histone Acetylation and Sensitivity to TORC1 Inhibition 
 
 tco89Δ cells are acutely sensitive to rapamycin and arsenic trioxide. Importantly, 
while these compounds are often grouped together as “TORC1 inhibitors”, the cellular 
response they elicit, and the way in which these signals are relayed throughout the cell, 
can vary significantly [314]. The effect of rapamycin on yeast TORC1 is well 
understood. FK506-associated rapamycin directly binds the Tor1 kinase via its FKBP-
rapamycin binding domain. Short term exposure results in transient G1-S cell cycle arrest, 
while long term TORC1 inhibition results in a G0 (or quiescence) response which proves 
inescapable if TORC1 function is compromised (i.e. tco89Δ). Arsenic trioxide’s effect on 
TORC1 is more unclear, though the majority of its phenotypes appear to be Sch9-
dependent [313]. The metalloid has been reported to promote a G2-M cell cycle arrest in 
cell culture models [342].  
 
 Interestingly, we demonstrate that the TORC1-PP6-sirtuin cascade delineated in 
Chapter 3 may contribute to cell-cycle re-entry following certain types of TORC1 stress, 
as tco89Δ hst3Δ and tco89Δ hst4Δ mutants are able to escape their reported arrests and 
grow similar to wild-type cells on both rapamycin and arsenic. We note that there are 
likely many other signaling molecules feeding into these processes, as tco89Δ hst3Δ or 
tco89Δ hst4Δ mutants are still sensitive to higher doses of rapamycin (10 nM, Figure 
3-18, top right panel). There is a precedent for Tap42-associated phosphatases regulating 
the cell cycle, as it was previously shown that the nitrogen responsive, Rim15-dependent 
phosphorylation of PP2A plays a critical role in cell entry and exit from quiescence 
[343]. We propose that sirtuin stabilization downstream of TORC1 inhibition may 
reinforce the cell-cycle exit observed in tco89Δ cells exposed to arsenic or rapamycin, in 
part through chromatin deacetylation. Further, we believe that the deletion of HST3 or 
HST4 in the tco89Δ background enables re-entry by promoting a hyperacetylated, 
transcriptionally permissive chromatin structure, devoid of barriers to the induction of 
genes required to exit cell-cycle arrest. Support for such a mechanism exists, as a similar 
observation was recently described in which carbon-responsive histone acetylation 
regulates transcription of the CLN3 cyclin to mediate reentry into the cell-cycle following 
glucose starvation [151]. A second explanation for the phenotypic rescue observed in the 
tco89Δ hst3Δ and tco89Δ hst4Δ is that, rather than loss of the sirtuins promoting exit from 
the transient cell-cycle arrest, the strains may simply be unable to initiate the arrest 
without these sirtuins. Previous reports have demonstrated that tco89Δ cells are also 
sensitive to the DNA damaging agent hydroxyurea [57], though the high throughput 
nature of the study makes it unclear as to whether treatment induces a cell cycle arrest 
similar to rapamycin, or if it promotes cell death. Similar to the findings with rapamycin 
and arsenic, the tco89Δ hst3Δ and tco89Δ hst4Δ strains show little sensitivity to 
hydroxyurea, which we hypothesize may be explained by restoration of H3K56ac, a 
chromatin mark essential for DNA repair. Indeed it has been previously shown that 
mimicking H3K56ac promotes resistance to DNA damaging agents [153]. In all, we find 
that preventing sirtuin activation downstream of TORC1 inhibition is sufficient to rescue 
sensitivity to rapamycin, arsenic trioxide and hydroxyurea, though likely through distinct 
mechanisms.  
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 Deletion of SIT4, the phosphatase identified as a regulator of sirtuin localization 
and stabilization, was sufficient to rescue tco89Δ’s growth on hydroxyurea and arsenic 
oxide. Unexpectedly though, it had no effect on rapamycin sensitivity. Resistance to 
hydroxyurea is likely due once again to H3K56ac, as was alluded to above. A previous 
work demonstrated that Sit4’s function in response to rapamycin is dependent on the 
identity of the associated Sap protein, which certainly implies the possibility of context-
specific functions [100]. To our knowledge, nobody has ever looked at how various 
TORC1 stressors affect Sit4-Sap interactions, but if arsenic and rapamycin have distinct 
effects on these dynamics, it could explain the observed plating phenotypes. Another 
possible explanation is that the Sit4 phosphatase, which is known to exist outside of 
Tap42, has both positive and negative functions in TORC1-dependent cell growth and the 
necessity of each depends on the nature of the stress. We speculate that one such positive 
function may be a feedback signal from the Tap42-phosphatases, or the downstream 
sirtuins, to Sch9. Indeed a similar mechanism has been identified in mammals, albeit for 
a different downstream mTORC1 effector, as SIRT1 activation in response to caloric 
restriction regulates the acetylation, and subsequent TORC1-dependent phosphorylation, 
of S6K1 (Ypk3 in yeast) [344-347]. Sch9 activity is known to be responsive to NAD+ 
homeostasis [348] (an essential co-factor for sirtuins), acetylation of its upstream 
regulator Sip2 [349], as well as direct phosphorylation by TORC1 [80]. Considering 
aforementioned evidence, we wonder whether in response to starvation, the activation of 
the Tap42-associated PP6 complex, and subsequent stabilization of sirtuins, may 
feedback onto Sch9 to silence any TORC1-independent activity that may arise while 
nutrients are limiting. If this were the case, in our tco89Δ sit4Δ strain, in addition to 
preventing the nuclear accumulation and stabilization of the sirtuins (reversing the 
hypoacetylation response), we are also allowing for low-level TORC1-independent 
activation of Sch9. This could enable these mutants to grow on arsenic trioxide since the 
majority of arsenic effects are Sch9 specific. However the reason why these cells do not 
grow on rapamycin may be due to the lack of signal continuity, as a cell’s ability to grow 
in the presence of rapamycin requires coordination of Sch9 and Tap42-associated 
phosphatases. Each of these effectors are known to regulate critical responses 
downstream of starvation. 
 
 In summary, the findings in Chapter 3 identify a novel signaling mechanism 
through which amino acid availability is sensed by TORC1 and relayed to chromatin in 
two parts. The initial PP6-dependent nuclear accumulation of Hst4 prompts rapid changes 
in site-specific acetylation of H3 and H4. The subsequent increase in Hst4 protein 
stability suggests that nuclear localization may shield Hst4 from proteasomal turnover. 
We believe that this influx of Hst4 sustains the hypoacetylation response until the 
environment is permissive for growth. Coordination of these dynamics appears to play a 
vital role in at least a subset of TORC1’s biological functions. 
 
 
Epigenetic Dysfunction and Cellular Transformation 
 
 It has been widely reported that a vast array of cancers display aberrant mTORC1 
function. This may occur in response to loss of function in the tumor suppressor PTEN, 
 78 
hyperactivation of PI3K, deletion of TSC1/2, or other genetic lesions that act to impair 
normal mTORC1 regulation. Accordingly, a sizable arsenal of mTORC1 inhibitors 
(“rapalogs”) have been developed and paired with just about every therapeutic 
imaginable in clinical trials. In addition to mTORC1 dysfunction, many tumors also 
display altered cellular metabolism and increased nitrogen requirements [350]. These 
changes would likely feed into sustaining mTORC1 activity and involve the amino acid 
sensing machinery at the lysosome. With this in mind, a new approach that is gaining 
traction involves targeting v-ATPase function to overcome drug resistance and prevent 
metastasis in a subset of cancers, including breast, non-small-cell lung, leukemia and 
sarcoma [351-357]. We speculate that at least some of the benefit observed from 
inhibition of the v-ATPase results from the corresponding reduction in mTORC1 
function. However our data also indicates that mTORC1-responsive acetylation is strictly 
downstream of amino acids, meaning that inhibiting the v-ATPase, rather than mTORC1, 
may produce discernible differences in the downstream cellular phenotype.  
 
 Indeed, a recent publication found that overexpression of the E2F1 transcription 
factor results in stimulation of v-ATPase activity, lysosomal reorganization, mTORC1 
activation and autophagic inhibition [358]. Interestingly however, these functions do not 
overlap substantially. Activation of mTORC1 involves altered lysosomal trafficking, 
while the activation of v-ATPase activity involves promoting the association of the V0 
and V1 subunits [358]. The authors speculate that pharmacological inhibition of the v-
ATPase may be beneficial in curbing metastasis in tumors overexpressing E2F1. This 
study beautifully illustrates how fully understanding a signaling pathway enables a more 
targeted therapeutic approach.  
 
 Considering what we now know about TORC1-mediated histone acetylation, and 
given that these modifications have been tied to transcription, chromatin remodeling, 
bromodomain docking, DNA repair, cell cycle progression and genomic stability, it is 
clear that epigenetic dysregulation downstream of hyperactive mTORC1 could play a 
significant role in disease pathogenesis. Such a relationship would explain the efficacy of 
combinatorial therapies pairing mTORC1 inhibitors with sirtuin activators [359-361]. It 
would be interesting to compare the epigenetic response elicited by rapamycin, 
bafilomycin A1 (v-ATPase inhibitor), or a combination of the two. We believe this area 
of study deserves considerable attention, as it would provide significant insight into 
downstream consequences of mTORC1 dysfunction while also illuminating a poorly 
understood molecular mechanism of cancer progression.  
 
 
TORC1-Dependent Acetylation Does Not Contribute to HMGB Chromatin Binding 
 
 In Chapter 4, we investigated whether the TORC1-PP6-Hst4 cascade described in 
Chapter 3 contributed to the seemingly TORC1-dependent chromatin association of 
HMGB proteins. Previous works demonstrated that H3K36 and H3K37, on the N-
terminal tail of histone H3, were critical for HMGB chromatin binding [252, 253]. We 
also knew that disruption of this site in yeast (H3K37A) paired with TORC1 inhibition 
led to dramatic HMGB (Nhp10) displacement and cell death [152]. We confirmed here 
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that this biological response also occurs with other HMGBs, as Nhp6a shuttles to the 
cytoplasm in response to rapamycin in the H3K37A strain, but not in the H3WT or 
H3K37R (restores protein-protein interactions) strains. This movement precedes the 
observed apoptotic and necrotic cell death, and similar timing was described for Nhp10 
[152]. To this point, the behavior of Nhp6a and Nhp10 in response to H3K37 mutation 
and TORC1 inhibition appear to mirror one and other.  
 
 We hypothesized that one reason TORC1 inhibition disrupts the chromatin 
binding of HMGBs is that the corresponding loss of acetylation, described in Chapter 3, 
may destabilize the association between HMGBs and the histone tail. Surprisingly 
though, combining H3K37A with hst4Δ or sap4Δ was not sufficient to suppress the HMG 
displacement or the apoptotic/necrotic cell death. We believe this is explainable by the 
fact that neither of these deletions completely restore acetylation under TORC1-
suppressive conditions (Figures 3-6, 3-10). Unfortunately, we were unable to create an 
H3K37A sit4Δ mutant, which is the combination which likely would have been the most 
promising given that acetylation in a sit4Δ is almost completely irresponsive to TORC1 
(Figure 3-5). It is possible that if we were to pre-treat H3K37A with nicotinamide prior 
to rapamycin exposure, we may see a reduction in HMG relocalization and/or cell death. 
We could pursue creating an H3K37A hst3Δ hst4Δ as well. 
 
 An important note to discuss is that until recently, HMGB1 nuclear release in 
mammals was believed to occur as a consequence of necrotic cell death. Once in the 
extracellular space, these proteins would function as signaling molecules to stimulate 
macrophage recruitment to clear the necrotic cells [251]. However, our timing 
experiments demonstrate that HMGB displacement in yeast occurs prior to induction of 
apoptosis and necrosis. This result leads us to propose that the nuclear to cytoplasmic 
movement of HMGs could be a contributing cause, rather than an effect, of cell death. 
With this new paradigm in mind, there are suddenly many new areas of study, including 
determining how the HMGs are inducing cell death (next section), and evaluating other 
potential intracellular signaling functions (e.g. bioenergetics, metabolism [255]) these 
molecules may possess. We can now begin to visualize a complex intracellular signaling 
web, centered on TORC1, which coordinates communication between the vacuole, the 
nucleus and the mitochondria to affect cell viability and lifespan.   
 
 One of the weaknesses of this section is that we do not provide unequivocal 
mechanistic evidence that the HMGBs are binding H3K37. Such experimental evidence 
could likely be achieved using recombinant wild-type or H3K37A containing 
nucleosomes and in vitro binding assays. Additionally, we do not understand yet where 
the HMGBs relocalize to following their exit from the nucleus, although this is an area 
we are currently pursuing. We propose future studies examining how cells respond to 
constitutively cytoplasmic/nuclear versions of these HMGBs to directly ask whether their 
altered subcellular distribution is causing the cell death observed in the rapamycin treated 
H3K37A cells. It would also be fascinating to pursue defining how decreased TORC1 
signaling synergizes with H3K37A to cause selective cytoplasmic localization of specific 
HMGBs. We have not completely ruled out the contribution of TORC1-dependent 
chromatin modifications, though it seems equally plausible that localization of the 
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HMGBs may be mediated via direct modification (TORC1-dependent phosphorylation, 
sirtuin-dependent deacetylation, etc.); a phenomena that has already been reported in 
metazoan cells [362]. 
 
 
Cells with Aberrant HMG Localization Undergo Massive Cell Death Characterized 
by Vacuolar Dysfunction and Hyperactive TORC1 
 
 Despite finding that the TORC1-dependent histone acetylation marks likely do 
not contribute directly to the association of HMGBs and the H3 N-terminal tail, we were 
still very interested in characterizing the cell death that appears to be triggered in 
response to their nuclear displacement. After all, these dynamics proved capable of 
turning low levels of rapamycin from a cytostatic agent to a cytotoxic agent. The 
potential therapeutic benefit of targeting the chromatin association of HMGBs was 
apparent, and served as a driving factor for the inquiries that followed.  
 
 We first demonstrated that the cell death response triggered by HMGB 
dislodgement is preceded by significant acidification of the vacuole (Figure 4-3). This 
was most clearly observable in rapamycin treated H3K37A cells, however there was an 
approximate two-fold increase in CFDA staining of mock treated H3K37A cells 
compared to the wild type control. A similar response was observed in H3WT cells 
expressing exogenous Nhp6a and Hmo1 from a plasmid. We subsequently found that 
mock treated H3K37A cells, and the Nhp6a/Hmo1-expressing H3WT cells, also display a 
somewhat surprising increase in TORC1 activity. It is clear this is an HMGB-dependent 
response, as the H3K37A nhp6aΔ and the H3K37A nhp10Δ do not display substantially 
increased TORC1 function. The idea that aberrant vacuolar pH and elevated TORC1 
signaling contributes to induction of cell death is supported by the fact that buffering the 
growth media was sufficient to reverse sensitivity to rapamycin (Figure 4-4).  
 
 We speculate that loss of vacuolar membrane integrity, leading to release of 
hydrolases/proteases and cellular acidification, may contribute to this HMGB-triggered 
programmed cell death. With the above concepts in mind, we propose that one possible 
destination for these displaced HMGBs may be the vacuole. There is, in fact, precedent 
for this concept. Mammalian inflammatory cells actively secrete HMGB1, and this 
process involves HMGB translocation from the nucleus to the lysosome in response to its 
acetylation [363, 364]. This intracellular shuttling is not limited to inflammatory cells 
though, as HMGB1 has also been shown to relocalize from the nucleus to the lysosome in 
the human peritoneal mesothelial cell line (HMrSV5), particularly in response to the 
availability of lipopolysaccharides [365]. These parallels provide support for the 
possibility that displaced yeast HMGBs are shuttling to the vacuole. This hypothesis is 
readily testable through co-localization studies incorporating fluorescent HMGB tags and 
vacuolar stains (FM4-64). Conversely, we could attempt to co-immunoprecipitate 
vacuole surface proteins and HMGBs. It is important to note that HMGB1 movement in 
mammals appears to be tied more to the secretory nature, rather than the pH, of the 
lysosome. However whether these functions are truly mutually exclusive remains to be 
seen.  
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 If we assume for a moment that the HMGBs are functioning as signaling 
molecules as they move from chromatin to the vacuole, we are still left to wonder what 
exactly they are doing to promote vacuole acidification and TORC1 function. One 
consideration is that the activation of TORC1 could simply be a physiological response to 
HMGB-mediated pH changes, which likely occur through modulation of the v-ATPase. 
We believe that fluctuations in pH, to an extent, may optimize conditions for the vacuolar 
proteases leading to a more active enzymatic compartment, increased protein breakdown 
and nitrogen availability, and enhanced TORC1 function. And while plausible, this 
hypothesis would seem to contradict work from Hughes et al. which demonstrated that as 
cells replicatively age, increased TORC1 signaling results in a more basic vacuolar pH 
[366]. This increase in pH, which can be reversed by inhibiting TOR, PKA or Sch9, 
contributes to cellular aging and mitochondrial dysfunction as a result of defective amino 
acid storage. We note that Hughes is presenting this data in a different model of aging 
(replicative vs. chronological), however the link between TORC1 and vacuolar pH is 
striking. Considering this, we propose an alternative explanation. The observed increase 
in TORC1 signaling may be a compensatory mechanism to prevent the apoptosis and 
necrosis that occurs as a result of HMGB displacement. This concept would be consistent 
with our results which demonstrate that buffering the growth media partially suppresses 
the cell death phenotype of H3K37A mutants treated with rapamycin. This would also be 
supported by the fact that H3K37A cells grow very much like wild-type under steady 
state conditions, despite vacuole morphological differences and modest HMGB 
displacement.  
 
 If HMGB release from chromatin proves to be a cell-death initiation signal in 
mammalian cells like it appears to be in yeast, it would certainly be an attractive 
pharmaceutical target. Displacement of HMGBs at low levels appears to be tolerable, but 
when paired with low-dose rapamycin, it initiates a cell death response. This observation 
suggests that if HMGB1 chromatin binding could be interrupted, it may allow for 
administration of reduced doses of rapamycin, which could hopefully circumvent some of 
the most compromising side effects. 
 
 
Mapping the Functional Domains of Tco89 
 
 In Chapter 5, we made significant strides toward understanding the yeast TORC1 
subunit, Tco89. The severe rapamycin sensitivity in tco89Δ cells is marked by a 
permanent exit from the cell cycle, as was discussed previously [43], and it is our hope 
that a more complete understanding of the subunit’s role in the complex will lead to the 
identification of a mammalian ortholog. Existence of such an ortholog seems likely given 
that every other yeast TORC1 component has a mammalian counterpart. The mammalian 
equivalent of Tco89 would be an attractive therapeutic target to sensitize cells with hyper 
mTORC1 function to TORC1 inhibitors.  
 
 Using vectors expressing the different Tco89 fragments proved challenging when 
mapping the region required for particular TORC1-dependent functions. This was due to 
the need to culture the cells in nutrient-defined media to select for the plasmids. The fact 
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that TORC1 activity is so heavily impacted by availability of nutrients means that many 
of our phenotypes are not nearly as pronounced in synthetic complete media as they are 
in nutrient rich media. This makes observing differences, and attributing them to 
particular protein fragments, quite arduous. If these obstacles could be overcome, by 
tweaking media conditions or integrating our mutants into the genomic locus, there are a 
number of very interesting studies that could be conducted. The most straightforward of 
which involve utilizing our different fragments to map Tco89’s structural and functional 
contributions to TORC1. We could use co-immunoprecipitation to assess which domain 
is required for Tco89 incorporation into TORC1, as well as to investigate how Tco89 
affects TORC1 complex stability by using Kog1 association with Lst8 as a readout. We 
have already mapped which portion is critical for regulating TORC1 function (via pS6 
blot) and growth on rapamycin (Figure 5-2), and it would be interesting to follow up and 
ask whether this same region (demarcated between fragments C and D) is involved in 
coordinating TORC1-dependent histone modifications. Notably, an earlier study utilizing 
much larger Tco89 fragments reported that residues 799-388 were responsible for 
interacting with Vac8 to promote the turnover of non-preferred carbon utilization 
enzymes [62]. This overlaps with our region of interest (532-399), and could provide 
insight as to how Tco89 coordinates the TORC1-dependent nutrient stress response. 
 
 We are enthusiastic about the identification of this minimal portion of Tco89 as 
we believe it can enlighten us to what its true function is, while also aiding in 
determining which downstream proteins are participating in this diverse signal relay 
system. Immunoprecipitation of a few different fragments (i.e. one that does rescue on 
rapamycin compared to one that does not) paired with mass spectrometric analysis could 
be incredibly powerful, enabling us to identify the physical interactions necessary for 
these phenotypes. Likely hits would include members of the TORC1 complex and EGO 
complex, but we speculate there are additional, yet to be determined binding partners of 
significant biological relevance. 
 
 tco89Δ mutants growth arrest at the G1-S boundary and enter a permanent 
quiescence-like state (yet remain viable) when exposed to rapamycin, and we would like 
to understand how this response is initiated and sustained. We first wondered whether the 
cell cycle defect could be explained by an inability to manage ROS production as 
metabolic requirements shifted. The tor1Δ mutant is known to decrease TORC1 activity 
and extend lifespan. It displays a distinct increase in log phase basal ROS but a 
significant reduction (compared to wild-type) in stationary phase ROS. These effects on 
reactive oxygen have been identified as potential explanations for the observed increase 
in lifespan of TORC1 mutants, which led us to investigate whether tco89Δ was deficient 
in these mitochondrial-based processes. Our data demonstrate that unlike tor1Δ, tco89Δ 
does not undergo a significant increase in log phase ROS. Though both mutants share a 
significant reduction in stationary phase ROS compared to the wild-type. It is currently 
unclear what is occurring in the tco89Δ strain, as it appears that ROS levels have been 
completely uncoupled from these metabolically distinct stages of growth. We speculate 
that deregulation of sirtuin-dependent acetylation of mitochondrial proteins, as discussed 
earlier in this chapter, may contribute to the relatively stagnant ROS production in 
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tco89Δ. This would be consistent with our previous result that showed TORC1-dependent 
H3K56ac is responsive to deletion of TCO89 but not TOR1 [66]. 
 
 Looking ahead, we are interested in investigating whether cellular growth and 
proliferation is sensitive to nutrients throughout the cell cycle, or if there is a defined 
window of time to arrest, after which the cell is committed to division regardless of 
nutrient availability. If we used ?-factor (G1) and nocodazole (G2-M) to arrest cells, then 
released them into media containing rapamycin and analyzed their cell cycle profile via 
flow cytometry, we could begin to understand this TORC1-dependent regulatory signal. 
For example, following ?-factor arrest, if tco89Δ cells exposed to rapamycin pass 
through S-phase and G2-M to finish their current cell division, it would suggest a brief 
window between mitosis and G1 at which cells assess their environmental conditions. If 
true, we would expect that cells arrested with nocodazole and released into rapamycin 
would complete mitosis and then enter G0.  
 
 In terms of sustaining the arrest, one possible explanation is that Tco89 
coordinates the dynamic association of Rho1 and Tap42 to TORC1. This intricate 
relationship is known to regulate the stress response [50]. In the absence of Tco89, cells 
grow normally under steady state conditions, but we speculate that once the stress 
response is initiated (i.e. rapamycin), it cannot be turned off. This leads to the permanent 
cell cycle arrest, despite cells retaining viability. This could be studied by labeling and 
co-immunoprecipitating Kog1 and Rho1, and Kog1 and Tap42 in the absence and 
presence of Tco89. We could then ask whether disruption of the Rho1 stress response 
prevents rapamycin effects on acetylation. Finally, we could examine how the sirtuins fit 
into all of these functions since we know deletion of HST3 and HST4 is sufficient to 
promote growth on low-level rapamycin. 
 
 We acknowledge there is still considerable work to be done, but the potential of 
this project excites us. Undoubtedly, with persistence this avenue will prove fruitful. The 
trials outlined here have equipped our lab with a unique set of tools and information that 
we believe will soon lead us to the most comprehensive mechanistic and structural 
understanding of Tco89 to date.  
 
 
Closing Remarks 
 
 It is becoming increasingly clear that the pathologies attributed to mTORC1 
dysfunction, including metabolic disorders, cancer, and cardiovascular disease, likely 
possess a degree of epigenetic deregulation that far exceeds what was previously known. 
While this dissertation focused on a single post-translational modification, on a defined 
series of histone substrates, there are almost certainly many more TORC1-dependent 
histone post-translational modifications that have yet to be discovered. We have 
speculated on a few potential non-histone acetylation targets earlier in this chapter as well 
(Ifh1, Spt7, mitochondrial proteins). Given the involvement of PP6, a phosphatase known 
to regulate a number of downstream TORC1 effectors, there is a likelihood that TORC1 
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activity could be translated into any number of epigenetic modifications beyond just 
acetylation, including methylation, phosphorylation, and ubiquitination.  
 
 The scientific funding and publishing bodies in this country have embraced high-
throughput sequencing techniques, which are costly, laborious to interpret for non-
bioinformaticians, and the results of which are often difficult to independently replicate. 
These technologies are immensely powerful, and they have led to some of the most 
compelling evidence of an epigenetic component to cancer; somatic mutations leading to 
an H3K27M substitution that drives gliomagenesis [367]. But the work presented in this 
dissertation illustrates how molecular biology is still a critical piece of the puzzle. There 
are reasons why combinatorial therapeutic approaches work but often times in the world 
of chemical screening and mouse modeling, the actual biology gets lost. If we understand 
how a signaling mechanism works under physiologically normal conditions, we know 
where to look when things begin to go awry.  
 
 It has truly been an honor working in such an elite, dynamic, rapidly expanding 
field with fantastic colleagues over the past five years. I look forward to seeing where the 
epigenetic community goes in the months and years to come.  
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APPENDIX A. SUPPLEMENTAL TABLES 
 
 
Table A-1. List of strains used in this study. 
 
Strain Genotype Source 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 OPEN Bio 
gat1Δ BY4741; gat1Δ::KanMX OPEN Bio 
gln3 Δ BY4741; gln3Δ::KanMX OPEN Bio 
hda1Δ BY4741; hda1Δ::KanMX OPEN Bio 
npr3Δ BY4741; npr3Δ::KanMX OPEN Bio 
ppg1Δ BY4741; ppg1Δ::KanMX OPEN Bio 
pph3Δ BY4741; pph3Δ::KanMX OPEN Bio 
rpd3Δ BY4741; rpd3Δ::KanMX OPEN Bio 
sap155Δ BY4741; sap155Δ::KanMX OPEN Bio 
sap185Δ BY4741; sap185Δ::KanMX OPEN Bio 
sap190Δ BY4741; sap190Δ::KanMX OPEN Bio 
sap4Δ BY4741; sap4Δ::KanMX OPEN Bio 
sch9Δ BY4741; sch9Δ::KanMX OPEN Bio 
sit4Δ BY4741; sit4Δ::KanMX OPEN Bio 
tco89Δ BY4741; tco89Δ::KanMX OPEN Bio 
tpd3Δ BY4741; tpd3Δ::KanMX OPEN Bio 
ure2Δ BY4741; ure2Δ::KanMX OPEN Bio 
H3G34A MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3G34A 
[315] 
H3V35A MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3V35A 
[315] 
H3K36A MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K36A 
[315] 
H3K37A MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37A 
[315] 
H3K37Q MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37Q 
[315] 
H3K37R MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37R 
[315] 
H3P38A MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3P38A 
[315] 
H3H39A MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3H39A 
[315] 
H3R40A MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3R40A 
[315] 
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H3WT MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3WT 
[315] 
YNL387 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::KanMX 
hst3Δ::NAT 
[66] 
YNL389 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::KanMX 
hst4Δ::NAT  
[66] 
Y3032 W303-1A tap42Δ::HIS3 pRS415-tap42-11 [309] 
Y3033 W303-1A tap42Δ::HIS3 pRS414-TAP42 [309] 
Y3034 W303-1A tap42Δ::HIS3 pRS414-tap42-106 [309] 
Y3035 W303-1A tap42Δ::HIS3 pRS414-tap42-109 [309] 
YNL251 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Sch9-6xHA::NAT  [304] 
YNL487 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT [304] 
YNL502 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT 
rpd3Δ::KanMX  
[304] 
YNL516 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT 
hst1Δ::KanMX  
[304] 
YNL517 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT 
sir2Δ::KanMX  
[304] 
YNL519 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT 
hst2Δ::KanMX  
[304] 
YNL541 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::HphNT1 
pnc1Δ::KanMX  
[304] 
YNL564 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 ρ- [304] 
YNL566 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::KanMX ρ- [304] 
YNL583 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT 
npr3Δ::KanMX 
[304] 
YNL612 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KanMX [304] 
YNL614 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst4-
9xMyc::KanMX 
[304] 
YNL622 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT  
sit4Δ::KanMX 
[304] 
YNL670 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT 
hda1Δ::KanMX  
[304] 
YNL676 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst3-
9xMyc::KanMX 
[304] 
YNL678 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst1-9xMyc::KanMX [304] 
YNL681 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst1-
9xMyc::KanMX 
[304] 
YNL685 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst2-9xMyc::KanMX [304] 
YNL687 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Sir2-9xMyc::KanMX [304] 
YNL689 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Sir2-
9xMyc::KanMX 
[304] 
YNL698 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst3-9xMyc::KanMX [304] 
YNL700 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst2-
9xMyc::KanMX 
[304] 
YNL714 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KanMX 
tco89Δ::NAT (MATED HAPLOIDS/SPORULATED) 
[304] 
YNL716 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::HYGRO 
sit4Δ::KANMX 
[304] 
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YNL718 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::HYGRO 
sit4Δ::KANMX tco89Δ:HphNT1 
[304] 
YNL775 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KANMX 
sap4Δ::HYGRO 
[304] 
YNL776 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KANMX 
sap4Δ::HYGRO tco89Δ::NAT 
[304] 
YNL778 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Maf1-9xMyc::NAT [304] 
YNL780 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Maf1-9xMyc::NAT 
sch9Δ KANMX 
[304] 
YNL465 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3WT hmo1Δ::KanMX 
This Study 
YNL467 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37A hmo1Δ::KanMX 
This Study 
YNL490 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3WT nhp10aΔ::KanMX 
This Study 
YNL491 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37A nhp10aΔ::KanMX 
This Study 
YNL512 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3WT nhp6aΔ::KanMX 
This Study 
YNL514 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37A nhp6aΔ::KanMX 
This Study 
YNL595 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3WT NHP6A-EGFP::KanMX 
This Study 
YNL596 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37A NHP6A-EGFP::KanMX 
This Study 
YNL653 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3WT sap4Δ::KanMX 
This Study 
YNL655 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37A sap4Δ::KanMX 
This Study 
YNL671 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37A hst4Δ::KanMX 
This Study 
YNL674 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3WT hst4Δ::KanMX 
This Study 
YNL710 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37R NHP6A-EGFP::KanMX 
This Study 
YNL722 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3WT NHP6A-yeGFP::HYGRO 
This Study 
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YNL723 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37A NHP6A-yeGFP::HYGRO 
This Study 
YNL724 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3WT hst4Δ::KanMX NHP6A-yeGFP::HYGRO 
This Study 
YNL725 MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]- 
ura3Δ H3K37A hst4Δ::KanMX NHP6A-yeGFP::HYGRO 
This Study 
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Table A-2. List of plasmids used in the study. 
 
Parent  Vector/Insert Source 
  pHmo1 Gal-HA Open Bio GAL1 collection 
  pNhp6A Gal-HA Open Bio GAL1 collection 
pRS416 pSCH9-6xHA [80] 
pJU790 pSCH9-6xHA (T723A, S726A, T737A, S758A, S765A) [80] 
pJU855 pSCH9-6xHA (T723D, S726D, T737E, S758E, S765E) [80] 
pRS416 pSit4FL FLAG This study 
pRS416 pTco89 N-term Myc full-length This study 
pRS416 pTco89 C-term FLAG full-length This study 
pRS416 pTco89 C-term FLAG Frag A  This study 
pRS416 pTco89 C-term FLAG Frag B  This study 
pRS416 pTco89 C-term FLAG Frag C  This study 
pRS416 pTco89 C-term FLAG Frag D  This study 
pRS416 pTco89 C-term FLAG Frag E  This study 
pRS416 pTco89 C-term FLAG Frag F  This study 
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APPENDIX B. SUPPLEMENTAL FIGURES 
 
 
 
 
Figure B-1. TORC1 inhibition over a range of rapamycin treatment conditions 
compared to a tco89Δ mutant. 
WT and tco89Δ were grown to log phase and then mock treated, or treated with 25 nM or 
300 nM rapamycin. Treatments shown represent resulting TORC1 activity following 20 
and 60 minutes inhibition.   
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Figure B-2. Control experiments for Sch92D3E expression vectors. 
A. sch9Δ cells were transformed with control vector (CV) or expression vectors 
containing various forms of Sch9 (see text for more details). Strains were grown in 
selective media to log phase and extracts were prepared and blotted to measure 
expression of mutant Sch9. G6PDH is included as an additional loading control. B. 
Strains from (A) were grown to stationary phase, five-fold serially diluted, and spotted 
onto selective media with a wide range of rapamycin concentrations. Plates with 
galactose and glycerol as the sole carbon sources are included as well. C. Wild-type 
Maf1-9xMyc and sch9Δ Maf1-9xMyc cells were transformed with the vectors from (A). 
Cells were grown to log phase, treated with 300 nM rapamycin for 60 min, and extracts 
were prepared. Samples were resolved on an 8% PAGE gel and blotted as shown. 
Reprinted with permission [304]. Workman, J.J., H. Chen, and R.N. Laribee, 
Saccharomyces cerevisiae TORC1 Controls Histone Acetylation by Signaling Through 
the Sit4/PP6 Phosphatase To Regulate Sirtuin Deacetylase Nuclear Accumulation. 
Genetics, 2016.  
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Figure B-3. Sirtuin relocalization in response to TORC1 inhibition. 
A-E. WT or tco89Δ strains, containing 9XMyc epitope tagged sirtuins, were treated as 
indicated at log phase, fixed, permeabilized, and imaged by indirect immunofluorescence 
as described in the Chapter 2. Images are representative of at least three independent 
biological replicates, and are a subset of the quantification shown in Figure 3-16. DAPI 
staining denotes the nucleus and the green channel (FITC-conjugated secondary to α-
Myc) tracks the localization of the sirtuins.  
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Figure B-3. Continued.   
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Figure B-3. Continued.   
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Figure B-4. Disruption of TORC1-responsive histone acetylation has no effect on 
H3K37A sensitivity to rapamycin. 
A. H3WT, H3K37A, H3WT hst4Δ, H3K37 hst4Δ, H3WT sap4Δ and H3K37A sap4Δ 
were grown to log phase. Samples were mock treated or treated with rapamycin (25 nM 
or 300 nM) for 5.5 hours or 24 hours as indicated. Following treatment, pellets were 
washed with sterile water and spotted onto YPD plates as described in Chapter 2. B. 
Strains from (A) were grown to stationary phase and spotted onto YPD and YPD 10 nM 
Rap plates. C. H3WT and H3K37A cells were grown and spotted as in (B) to the plate 
media denoted. Photos are provided for rapidly growing strain/media combinations at 2 
days, and at 6 days for the more sensitive pairings.   
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Figure B-5. Galactose-inducible HMGB expression vectors promote aberrant 
protein levels and distribution of Hmo1 and Nhp6A even prior to addition of 
galactose.  
H3WT cells were transformed with control vector, or galactose inducible expression 
vectors containing HA-tagged Hmo1 or Nhp6A. Strains were grown to log phase in 
synthetic complete raffinose media, and then mock treated or induced with 2% galactose 
for 20 minutes. Cells were fixed, processed by indirect immunofluorescence, and imaged 
by confocal microscopy, as described in Chapter 2. Images are representative of three 
independent experiments. DAPI staining denotes the nucleus and the green channel 
(FITC-conjugated secondary to α-HA) marks the localization of the HMGBs. 
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